Aradigm (ARDMQ) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 06, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'ARADIGM CORP	'	'
Entity Central Index Key	'0001013238	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	587,252,904	'
Entity Public Float	'	'	$40,385,155

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$48,131	$7,414
Short-term investments	'	203
Receivables	92	41
Prepaid and other current assets	1,448	106
Total current assets	49,671	7,764
Property and equipment, net	400	727
Other assets	353	475
Total assets	50,424	8,966
Current liabilities:	'	'
Accounts payable	619	330
Accrued clinical and cost of other studies	1,831	500
Accrued compensation	198	184
Deferred revenue	4,379	'
Facility lease exit obligation	168	144
Other accrued liabilities	82	127
Total current liabilities	7,277	1,285
Deferred rent, non-current	132	144
Facility lease exit obligation, non-current	297	465
Note payable and accrued interest	9,035	8,513
Total liabilities	16,741	10,407
Commitments and contingencies (Note 8)	'	'
Shareholders' equity (deficit):	'	'
Preferred stock, 5,000,000 shares authorized, none outstanding	'	'
Common stock, no par value; authorized shares: 1,001,830,627 at December 31, 2013 and 297,527,214 at December 31, 2012; issued and outstanding shares: 587,252,904 at December 31, 2013; 251,346,385 at December 31, 2012	426,607	369,919
Accumulated deficit	-392,924	-371,360
Total shareholders' equity (deficit)	33,683	-1,441
Total liabilities and shareholders' equity (deficit)	$50,424	$8,966

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	'	'
Common stock, par value	'	'
Common stock, shares authorized	1,001,830,627	297,527,214
Common stock, shares issued	587,252,904	251,346,385
Common stock, shares outstanding	587,252,904	251,346,385

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Revenue:	'	'
Contract revenue	$8,672	'
Royalty revenue	1,045	1,007
Total revenues	9,717	1,007
Operating expenses:	'	'
Research and development	8,884	3,781
General and administrative	4,775	3,896
Collaboration arrangement acquisition cost	15,943	'
Restructuring and asset impairment	27	34
Total operating expenses	29,629	7,711
Loss from operations	-19,912	-6,704
Interest income	6	10
Interest expense	-1,649	-1,530
Other expense, net	-9	-2
Net loss	-21,564	-8,226
Change in unrealized losses on available-for-sale securities	'	-1
Comprehensive loss	($21,564)	($8,227)
Basic and diluted net loss per common share	($0.06)	($0.04)
Shares used in computing basic and diluted net loss per common share	366,165	201,310

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (Deficit) (USD $)	Total	Common stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning Balance at Dec. 31, 2011	$689	$363,822	$1	($363,134)
Beginning Balance, Shares at Dec. 31, 2011	'	198,831,216	'	'
Issuance of common stock in a private offering, net of issuance costs	5,547	5,547	'	'
Issuance of common stock in a private offering, net of issuance costs, Shares	'	50,000,000	'	'
Issuance of common stock under the employee stock purchase plan	77	77	'	'
Issuance of common stock under the employee stock purchase plan, Shares	'	630,752	'	'
Issuance of restricted stock awards, Shares	'	1,884,417	'	'
Stock-based compensation	473	473	'	'
Net loss	-8,226	'	'	-8,226
Unrealized loss on available-for-sale investments	-1	'	-1	'
Ending Balance at Dec. 31, 2012	-1,441	369,919	'	-371,360
Ending Balance, Shares at Dec. 31, 2012	'	251,346,385	'	'
Issuance of common stock in a private offering, net of issuance costs	40,227	40,227	'	'
Issuance of common stock in a private offering, net of issuance costs, Shares	'	333,968,104	'	'
Issuance of common stock under the employee stock purchase plan	95	95	'	'
Issuance of common stock under the employee stock purchase plan, Shares	'	865,082	'	'
Issuance of restricted stock awards	'	'	'	'
Issuance of restricted stock awards, Shares	'	1,213,333	'	'
Cancellation of restricted stock awards	'	'	'	'
Cancellation of restricted stock awards, Shares	'	-150,000	'	'
Exercise of options	2	2	'	'
Exercise of options, Shares	10,000	10,000	'	'
Stock-based compensation	421	421	'	'
Stock discount on Grifols arrangement	15,943	15,943	'	'
Net loss	-21,564	'	'	-21,564
Ending Balance at Dec. 31, 2013	$33,683	$426,607	'	($392,924)
Ending Balance, Shares at Dec. 31, 2013	'	587,252,904	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($21,564)	($8,226)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'	'
Amortization and accretion of investments	29	14
Depreciation and amortization	370	391
Stock-based compensation expense	421	473
Collaboration arrangement acquisition cost	15,943	'
Amortization of note discount	94	59
Changes in operating assets and liabilities:	'	'
Receivables	-49	-5
Prepaid and other current assets	-1,342	55
Other assets	121	107
Accounts payable	289	134
Accrued compensation	14	-11
Accrued liabilities	1,714	466
Deferred rent	-12	12
Deferred revenue	4,379	'
Facility lease exit obligation	-143	-120
Net cash provided by (used in) operating activities	264	-6,651
Cash flows from investing activities:	'	'
Capital expenditures	-43	-5
Purchases of available-for-sale investments	-2,852	-2,502
Proceeds from maturities of available-for-sale investments	3,026	8,800
Net cash provided by investing activities	131	6,293
Cash flows from financing activities:	'	'
Proceeds from private offering of common stock, net	40,227	5,547
Proceeds from issuance of common stock to Employee Stock Purchase Plan	95	77
Net cash provided by financing activities	40,322	5,624
Net increase in cash and cash equivalents	40,717	5,266
Cash and cash equivalents at beginning of year	7,414	2,148
Cash and cash equivalents at end of year	$48,131	$7,414

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	1. Organization and Summary of Significant Accounting Policies
	Organization
	Aradigm Corporation (the “Company”) is a California corporation, incorporated in 1991, focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The Company’s principal activities to date have included conducting research and development and developing collaborations. Management does not anticipate receiving revenues from the sale of any of its products in the upcoming year. The Company operates as a single operating segment.
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All inter-company accounts and transactions have been eliminated in consolidation.
	Liquidity and Financial Condition
	The Company has incurred significant operating losses and negative cash flows from operations. At December 31, 2013, the Company had an accumulated deficit of $392.9 million, working capital of $42.4 million and shareholders’ equity of $33.7 million. The Company believes that its cash and cash equivalents totaling $48.1 million as of December 31, 2013 will be sufficient to fund its operations at least through 2014. However, the Company’s business strategy may require it to , or it may otherwise determine to, raise additional capital at any time through equity financing(s), strategic transactions or otherwise. Such additional funding may be necessary to develop the Company’s potential product candidates. In addition, the Company may determine to raise capital opportunistically.
	Use of Estimates
	The preparation of financial statements, in conformity with United States generally accepted accounting principles, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, and income taxes. Actual results could differ from these estimates.
	Cash Equivalents
	All highly liquid investments with maturities of three months or less at the time of purchase are classified as cash equivalents.
	Investments
	Management determines the appropriate classification of the Company’s marketable securities, which consist solely of debt securities, at the time of purchase. All marketable securities are classified as available-for-sale, carried at estimated fair value and reported in short-term investments. Unrealized gains and losses on available-for-sale securities are excluded from earnings and losses and are reported as a separate component in the statement of shareholders’ equity (deficit) until realized. Fair values of investments are based on quoted market prices where available. Investment income is recognized when earned and includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. When the Company determines that the decline in fair value of an investment below the Company’s accounting basis is other-than-temporary, the Company reduces the carrying value of the securities held and records a loss in the amount of any such decline. No such reductions have been required during any of the periods presented.
	Property and Equipment
	The Company records property and equipment at cost and calculates depreciation using the straight-line method over the estimated useful lives of the respective assets. Machinery and equipment includes external costs incurred for validation of the equipment. The Company does not capitalize internal validation expense. Computer equipment and software includes capitalized computer software. All of the Company’s capitalized software is purchased; the Company has no internally developed computer software. Leasehold improvements are depreciated over the shorter of the term of the lease or useful life of the improvement.
	The estimated useful lives of property and equipment are as follows:
	Computer equipment and software	3 to 5 years
	Furniture and fixtures	5 to 7 years
	Lab equipment	5 to 7 years
	Machinery and equipment	5 years
	Leasehold improvements	5 to 17 years
	Impairment of Long-Lived Assets
	The Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values and the loss is recognized in the consolidated statements of operations.
	Accounting for Costs Associated with Exit or Disposal Activities
	The Company recognizes a liability for the cost associated with an exit or disposal activity that is measured initially at its fair value in the period in which the liability is incurred. The Company accounted for the partial sublease of its headquarters building as an exit activity and recorded the sublease loss in its statement of operations and comprehensive net loss (see Note 5).
	Costs to terminate an operating lease or other contracts are (a) costs to terminate the contract before the end of its term or (b) costs that will continue to be incurred under the contract for its remaining term without economic benefit to the entity. In periods subsequent to initial measurement, changes to the liability are measured using the credit adjusted risk-free rate that was used to measure the liability initially.
	Revenue Recognition
	Contract revenues consist of revenues from grants, collaboration agreements and feasibility studies. License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of our product candidates. The terms of the agreement typically include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones and royalties on net product sales. The Company recognizes revenue under the provisions of the Securities and Exchange Commission issued Staff Accounting Bulletin 104, Topic 13, Revenue Recognition Revised and Updated (“SAB Topic 13”) and ASC 605-25, Revenue Recognition-Multiple Elements. Revenue for arrangements not having multiple deliverables, as outlined in ASC 605-25, is recognized once costs are incurred and collectability is reasonably assured.
	Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured. Multiple-deliverable arrangements, such as license and development agreements, are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price method and the appropriate revenue recognition principles are applied to each unit. When the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized.
	The Company estimates its performance period used for revenue recognition based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Significant management judgment may be required to determine the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.
	The Company prospectively adopted the provisions of Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605); Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) for new and materially modified arrangements originating on or after January 1, 2010. ASU 2009-13 provides updated guidance on how the deliverables in an arrangement should be separated, and how consideration should be allocated, and it changes the level of evidence of standalone selling price required to separate deliverables by allowing a vendor to make its best estimate of the standalone selling price of deliverables when vendor-specific objective evidence or third-party evidence of selling price is not available.
	The Company allocates non-contingent consideration to each stand-alone deliverable based upon the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using vendor-specific objective evidence, or VSOE, of selling price, if it exists, or third-party evidence, or TPE, of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, the Company uses best estimated selling price, or BESP, for that deliverable.
	Assuming the elements meet the revenue recognition guidelines, the revenue recognition methodology prescribed for each unit of accounting is summarized below:
	Upfront Fees—The Company defers recognition of non-refundable upfront fees if there are continuing performance obligations without which the technology licensed has no utility to the licensee. If the Company has continuing performance obligations through research and development services that are required because know-how and expertise related to the technology is proprietary to the Company, or can only be performed by the Company, then such up-front fees are deferred and recognized over the estimated period of the performance obligation. The Company bases the estimate of the period of performance on factors in the contract. Actual time frames could vary and could result in material changes to the results of operations. When the collaboration partners request the Company to continue performing the research and development services in collaboration beyond the initial period of performance the remaining unamortized deferred revenue and any new continuation or license fees are recognized over the extended period of performance.
	Funded Research and Development—Revenue from research and development services is recognized during the period in which the services are performed and is based upon the number of full-time-equivalent personnel working on the specific project at the agreed-upon rate. The full-time equivalent amount can vary each year if the contracts allow for a percentage increase determined by relevant salary surveys, if applicable. Reimbursements from collaborative partners for agreed upon direct costs including direct materials and outsourced, or subcontracted, pre-clinical studies are classified as revenue and recognized in the period the reimbursable expenses are incurred. Payments received in advance are recorded as deferred revenue until the research and development services are performed or costs are incurred.
	Milestones—Substantive milestone payments are considered to be performance bonuses that are recognized upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; substantive effort is involved in achieving the milestone; the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and a reasonable amount of time passes between the up-front license payment and the first milestone payment as well as between each subsequent milestone payment. If any of these conditions are not met, the milestone payments are deferred and recognized as revenue over the term of the arrangement as the Company completes its performance obligations.
	Royalties—The Company recognizes royalty revenues from licensed products upon the sale of the related products.
	Research and Development
	Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs as such costs are incurred.
	Stock-Based Compensation
	The Company accounts for share-based payment arrangements in accordance with ASC 718, Compensation-Stock Compensation and ASC 505-50, Equity-Equity Based Payments to Non-Employees which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments including stock options and restricted stock awards and stock issued under the Employee Stock Purchase Plan (“ESPP”). These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 9 for further discussion of the Company’s stock-based compensation plans.
	Income Taxes
	The Company makes certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of the recognition of revenue and expense for tax and financial statement purposes. As part of the process of preparing the financial statements, the Company is required to estimate its income taxes in each of the jurisdictions in which it operates. This process involves the estimation of the current tax exposure under the most recent tax laws and assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities which are included in the Company’s consolidated balance sheets.
	The Company assesses the likelihood that it will be able to recover its deferred tax assets. The Company considers all available evidence, both positive and negative, including its historical levels of income and losses, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. If the Company does not consider it more likely than not that it will recover its deferred tax assets, it will record a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. At December 31, 2013 and 2012, the Company believed that the amount of its deferred income taxes would not be ultimately recovered. Accordingly, the Company recorded a full valuation allowance for deferred tax assets. However, should there be a change in the Company’s ability to recover its deferred tax assets, it would recognize a benefit to its tax provision in the period in which it determines that it is more likely than not that it will recover its deferred tax assets.
	Net Loss Per Common Share
	Basic net loss per common share is computed using the weighted-average number of shares of common stock outstanding less the weighted-average number of shares subject to repurchase. Unvested restricted stock awards subject to repurchase totaled 769,000 shares and 1,453,000 shares for the years ended December 31, 2013 and 2012, respectively. Potentially dilutive securities were not included in the net loss per share calculation for the years ended December 31, 2013 and 2012 because the inclusion of such shares would have had an anti-dilutive effect.
	Potentially dilutive securities include the following (in thousands):
		Years Ended December 31,
		2013		2012
	Outstanding stock options		7,766		6,755
	Unvested restricted stock awards		769		1,453
	Outstanding warrants		2,841		2,841
	Significant Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with these instruments are mitigated by banking with, and only purchasing commercial paper and corporate notes from, creditworthy institutions. The maximum amount of loss due to credit risk associated with these financial instruments is their respective fair values as stated in the accompanying Consolidated Balance Sheets.
	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income requires that an entity’s change in equity or net assets during a period from transactions and other events from non-owner sources be reported. The Company reports unrealized gains or losses on its available-for-sale securities as other comprehensive income (loss). Total comprehensive income (loss) has been disclosed on the Consolidated Statement of Operations and Comprehensive Loss.
	Recently Issued Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the year ended December 31, 2013 that are of significance, or potential significance to the Company.

Cash_Cash_Equivalents_and_Shor

Cash, Cash Equivalents and Short-term Investments	12 Months Ended
	Dec. 31, 2013
Cash And Cash Equivalents [Abstract]	'
Cash, Cash Equivalents and Short-term Investments	'
	2. Cash, Cash Equivalents and Short-term Investments
	A summary of cash and cash equivalents and short-term investments, classified as available-for-sale and carried at fair value is as follows (in thousands):
		Amortized		Gross		Gross		Estimated
		Cost		Unrealized		Unrealized		Fair Value
				Gain		(Loss)
	December 31, 2013
	Cash and cash equivalents	$	48,131	$	—	$	—	$	48,131
	December 31, 2012
	Cash and cash equivalents	$	7,414	$	—	$	—	$	7,414
	Short-term investments:
	U.S. Treasury notes	$	203		—		—	$	203
	Total	$	7,617	$	—	$	—	$	7,617
	All short-term investments at December 31, 2012 mature in less than one year. Unrealized holding gains and losses on securities classified as available-for-sale are recorded in accumulated other comprehensive income (loss).

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	The Company follows ASC 820, Fair Value Measurement which clarifies the definition of fair value, prescribes methods for measuring fair value, establishes a fair value hierarchy based on the inputs used to measure fair value and requires certain disclosures about the use of fair value measurements. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value. Level 1 values are based on quoted prices in active markets. Level 2 values are based on significant other observable inputs. Level 3 values are based on significant unobservable inputs. The following table presents the fair value level for the cash and cash equivalents and short-term investments which represents the assets that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. The Company does not have any liabilities that are measured at fair value.
	Description	Balance		Level 1		Level 2		Level 3
		December 31,
		2013
		(In thousands)
	Cash and cash equivalents	$	48,131	$	48,131	$	—	$	—
	The Company’s cash and cash equivalents at December 31, 2013 consist of cash and money market funds. Money market funds are valued using quoted market prices. The Company uses an independent third party pricing service to value these securities. The pricing service uses observable inputs such as new issue money market rates, adjustment spreads, corporate actions and other factors and applies a series of matrices pricing model. The Company performs a review of prices reported by the pricing service to determine if they are reasonable estimates of fair value. In addition, the Company performs a review of its securities to determine the proper classification in accordance with the fair value hierarchy.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	4. Property and Equipment
	Property and equipment consist of the following (in thousands):
		December 31,
		2013			2012
	Machinery and equipment	$	4,412		$	4,385
	Furniture and fixtures		1,138			1,138
	Lab equipment		2,138			2,138
	Computer equipment and software		2,651			2,640
	Leasehold improvements		1,844			1,839
	Property and equipment		12,183			12,140
	Less accumulated depreciation and amortization		(11,783	)		(11,413	)
	Property and equipment, net	$	400		$	727
	Depreciation expense was $370,000 and $391,000 for the years ended December 31, 2013 and 2012, respectively.

Sublease_Agreement_and_Lease_E

Sublease Agreement and Lease Exit Liability	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Sublease Agreement and Lease Exit Liability	'
	5. Sublease Agreement and Lease Exit Liability:
	On July 18, 2007, the Company entered into a sublease agreement with Mendel Biotechnology, Inc. (“Mendel”) to lease approximately 48,000 square feet of the Company’s 72,000 square foot headquarters facility located in Hayward, California. In April 2009, the Company entered into an amendment to its sublease agreement with Mendel to sublease an additional 1,550 square feet. The Company recorded an additional sublease loss on the amendment since the monthly payments the Company expects to receive are less than what the Company will owe the lessor for the subleased space. In January 2012, the Company entered into a second amendment to the sublease with Mendel in which Mendel leased an additional 3,300 square feet and at this time Mendel waived their right to early termination. The sublease with Mendel now expires concurrently with the Company’s master lease for the Hayward facility.
	During the year ended December 31, 2007, the Company recorded a $2.1 million lease exit liability and related expense for the expected loss on the sublease, in accordance with ASC 420 Exit or Disposal Cost Obligations, because the monthly payments the Company expects to receive under the sublease are less than the amounts that the Company will owe the lessor for the sublease space. The fair value of the lease exit liability was determined using a credit-adjusted risk-free rate to discount the estimated future net cash flows, consisting of the minimum lease payments to the lessor for the sublease space and payments the Company will receive under the sublease. The sublease loss and ongoing accretion expense required to record the lease exit liability at its fair value using the interest method have been recorded as part of restructuring and asset impairment expense in the Consolidated Statement of Operations and Comprehensive Loss. The lease exit liability activity for the years ended December 31, 2013 and 2012 are as follows (in thousands):
		Year Ended December 31,
		2013			2012
	Balance at beginning of year	$	609		$	729
	Accretion expense		26			34
	Lease payments		(170	)		(154	)
	Balance at end of the year	$	465		$	609
	The Company classified $168,000 of the $465,000 lease exit liability in current liabilities and the remaining $297,000 in non-current liabilities in the accompanying consolidated balance sheet at December 31, 2013.

Collaboration_Agreement

Collaboration Agreement	12 Months Ended
	Dec. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Collaboration Agreement	'
	6. Collaboration Agreement
	Grifols License and Collaboration Agreement
	On May 20, 2013, the Company and Grifols, S.A., (“Grifols”) and certain other investors (the “Investors”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”), pursuant to which the Company agreed, subject to the terms and conditions set forth in the Stock Purchase Agreement, to issue and sell a total of 209,774,558 shares of the Company’s common stock (“Common Stock”), to Grifols and an additional 124,193,546 shares of Common Stock to the Investors, for a total sale of 333,968,104 shares of Common Stock (the “Company Stock Sale”), for a purchase price of $0.124 per share. The aggregate gross consideration paid to the Company in August 2013 in the Company Stock Sale was approximately $41.4 million.
	In conjunction with signing the Stock Purchase Agreement, the Company and Grifols agreed to enter into a License and Collaboration Agreement (the “License Agreement”) at the closing of the Company Stock Sale. The License Agreement would exclusively license the Company’s inhaled liposomal ciprofloxacin compounds for the indication of non-cystic fibrosis bronchiectasis and other indications (the “Program”) to Grifols on a worldwide basis. Grifols would fund development expenses and commercialize products from the Program (“Products”), and pay development milestones and royalties on future commercial sales of Products. The License Agreement is described further below.
	The Company held a special meeting of its shareholders on July 15, 2013 to (i) approve certain amendments to the Company’s charter, including amendments necessary to increase the total number of shares of Common Stock authorized to be issued by the Company to at least 706,830,627 shares, including the 333,968,104 shares to be sold in the Company Stock Sale (the “Charter Amendment”) and (ii) to approve the Company’s closing of the Company Stock Sale and entering into the License Agreement, Governance Agreement and other agreements described below and in the Stock Purchase Agreement (the “Transactions”). Shareholders of the Company holding more than 50% of the outstanding shares of the Company’s Common Stock voted in favor of these proposals at the special meeting.
	The closing of the Transactions was subject to certain closing conditions, including, among others the Company’s entering into binding terms with a third party to commercially manufacture Products to permit the Company to satisfy its obligation to commercially supply Grifols with Products. All conditions to the closing of the Transactions were met as of August 27, 2013 and the Company Stock Sale was completed on August 27, 2013.
	Grifols paid approximately $26.0 million for the shares of the Company’s common stock at a purchase price of $0.124 per share, which reflected the contractual price for the Company’s common stock as stated in the Stock Purchase Agreement on May 20, 2013. Following the announcement of the collaboration, execution of a supply agreement and satisfaction of the other conditions of closing, the stock price rose to $0.20 at the time of closing. Consequently, the contractual price of $0.124 per share resulted in a $0.076 per share discount from the August 27, 2013 closing price of $0.20 per share, or a discount of approximately $15.9 million from the fair market value of the common stock on the effective date of the Grifols License and Collaboration Agreement. The Company determined this transaction was not within the scope of ASC 605-25 and accordingly, the Company recorded the sale of common stock to Grifols at fair value based on the closing price of the Company’s stock on August 27, 2013 at $0.20 per share. This discount, which is a non-cash charge, has been recorded as Collaboration Arrangement Acquisition Cost in the Company’s Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2013.
	License Agreement
	The License Agreement was signed simultaneously with the closing of the Company Stock Sale. Under the License Agreement, the Company granted to Grifols an exclusive license to the Program, the lead product candidate of which is named Pulmaquin®. The license permits Grifols to commercialize Products throughout the world and grants Grifols a back-up manufacturing right to produce Products.
	The Company is responsible for developing the Product for non-cystic fibrosis bronchiectasis or pulmonary infections associated with non-cystic fibrosis bronchiectasis, in accordance with an agreed upon development plan and pursuant to a Grifols-funded budget of $65 million (which includes allocations for the Company’s internal, fully-burdened expenses). Any excess expenses are the responsibility of the Company. The Company will develop the Product for additional indications at Grifols’ sole expense if Grifols elects to pursue such development.
	The Company is responsible for obtaining regulatory approval of the first indication for the Product in the United States and the European Union. Grifols is responsible for additional regulatory expenses, including the cost of obtaining approval outside the United States and European Union, and the cost of maintaining approvals globally. Grifols is responsible to use diligent efforts to commercialize the Product in countries where regulatory approval has been obtained.
	The Company is responsible for supplying Grifols’ requirements of the Product, and must establish primary and back-up suppliers acceptable to Grifols. Grifols will purchase Products from the Company on a cost pass-through basis plus a margin.
	The collaboration between Grifols and the Company is governed by a joint committee comprised of equal representation by the Company and Grifols and operated on a consensus basis. In the event that the parties do not agree, Grifols has deciding authority, except with respect to specific matters specified in the License Agreement. The Company has no obligation to participate in the joint committee after the first commercial sale of the product, but may do so at its discretion. Accordingly, the Company determined that it can separate performance obligations that occur over the development period from performance obligations that will occur during the commercialization period.
	With respect to the US and EU development and approval of Pulmaquin for non-cystic fibrosis bronchiectasis management, Grifols will pay to Aradigm reimbursements of development costs up to $65 million and development milestone payments of up to $25 million. Additionally, royalty payments on a country-by-country basis on net sales at a rate of either 12.5% or 20% (depending on the amount of net sales) for so long as there is patent coverage or orphan drug designation (or, if longer, 10 years), except that payments will be reduced by half on a country-by-country basis in the event that another inhaled liposomal product containing ciprofloxacin is being sold for an indication for which the Aradigm product has regulatory approval. Royalty payments may also be reduced by 50% if Aradigm has no valid patent claim or orphan drug protection in that country.
	The Company’s deliverables include an exclusive license for inhaled ciprofloxacin compounds for the indication of non-cystic fibrosis bronchiectasis and other indications, reimbursement of development costs up to $65 million and participation on a Joint Steering Committee (“JSC”). Having determined that both the development and JSC do not have standalone value from the license, the Company combined these deliverables into a single unit of accounting. The Company is recognizing reimbursements of development expenses as collaboration services are performed and costs are incurred. During the year ended December 31, 2013, the Company recognized $8.7 million in contract revenue related to services performed and costs incurred during the year as well as costs incurred from the period August 1, 2012 to June 30, 2013, which were reimbursable under the terms of the License Agreement. Revenue has been recognized under the License Agreement at December 31, 2013 as follows: the Company has a deferred revenue balance as of December 31, 2013 of $4.4 million for reimbursements billed in advance of performance of collaboration services and in advance of incurring costs and expenses for the year ended December 31, 2013 and has recognized contract revenues of $8.7 million in the year ended December 31, 2013 for the reimbursement of fully burdened development expenses for collaboration services performed and costs incurred related to development of Pulmaquin for non-cystic fibrosis bronchiectasis prior to execution of the License Agreement on August 27, 2013 and through the year ended December 31, 2013.
	Costs incurred under the Grifols License Agreement in the years ended December 31, 2013 and 2012 are $7.6 million and $1.1 million. Development expenses are fully burdened and include direct costs reported as research and development expenses and collaboration-related general and administrative expenses. Contract revenue in the year ended December 31, 2013 includes a total of $1.1 million, respectively for reimbursement of direct costs reported as research and development expenses incurred in the year ended December 31, 2012.
	Option Agreement
	Simultaneously with execution of the License Agreement, Aradigm entered into an Option Agreement (the “Option Agreement”) with Grifols granting Grifols a limited term option to license Aradigm’s AERx pulmonary drug delivery platform for use with another molecule. The Option Agreement affords Grifols a limited period of time to conduct a diligence assessment. If Grifols elects to proceed with a license, Grifols will pay Aradigm a low single digit royalty on net sales but bear all costs associated with development and commercialization.
	Governance Agreement
	The Governance Agreement sets forth certain rights and obligations of the Company and Grifols concerning, among other things, certain corporate governance matters, certain limitations on future acquisitions of shares of Common Stock by Grifols, and certain rights by Grifols to maintain a target level of ownership in the Company.
	On the date the Governance Agreement was executed, the Company’s board of directors was reconstituted to consist of its chief executive officer, three independent directors under the NASDAQ Marketplace Rules and two persons designated by Grifols. The number of persons Grifols is entitled to designate for consideration for election to the Company’s board of directors by the Company’s nominating committee will thereafter depend on the percentage of beneficial ownership of the Company held by Grifols.
	The Governance Agreement also provides that during the period beginning on the date of Closing and ending 12 months after the first commercial sale of a Product (the “Restricted Period”), Grifols will not directly or indirectly acquire or offer to acquire any shares of Common Stock except (i) with the approval of the Company’s board of directors and a majority of its independent directors, (ii) effected solely to the extent necessary to maintain the beneficial ownership of Grifols and its affiliates at an amount equal to 35% (the “Target Percentage”) of the shares of Common Stock on a Fully Diluted Basis (as defined in the Governance Agreement), or (iii) in order to maintain its ownership percentage in the event that the Company issues new securities, in accordance with the provisions of the Governance Agreement. The Restricted Period terminates upon the occurrence of certain events, including a change in control of the Company and a third party publicly proposing to acquire the Company. The Governance Agreement further imposes certain “standstill” obligations on Grifols during the Restricted Period, pursuant to which Grifols and certain related persons are prohibited from soliciting proxies from the Company’s shareholders, granting proxies or entering into voting agreements and seeking additional representation on the Company’s Board of Directors.
	The Governance Agreement provides Grifols with certain preemptive rights to participate in future issuances of Common Stock or equivalents of Common Stock by the Company, or the right to acquire shares of Common Stock from third parties or on the open market to maintain its Fully Diluted Ownership at the Target Percentage.
	The Governance Agreement requires the approval of Grifols for certain actions by the Company which would adversely affect Grifols’ rights under the Governance Agreement, and for the Company to terminate the employment of its Chief Executive Officer or to appoint any successor Chief Executive Officer.
	Registration Rights Agreements
	In connection with and concurrently with the closing of the Company Stock Sale, the Company entered into a Registration Rights Agreement with Grifols (the “Grifols Registration Rights Agreement”), pursuant to which the Company agreed to provide registration rights to Grifols with respect to the shares of Common Stock to be acquired in the Company Stock Sale. Under such agreement, Grifols will be entitled to require the Company to file with the SEC certain registration statements under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the resale of the shares of Common Stock acquired by Grifols in the Company Stock Sale up to three times on Form S-1 and up to six times on Form S-3, and to include its shares of Common Stock in any registration the Company proposes for its own account or for the account of one or more of its shareholders.
	In connection with and concurrently with the closing of the Company Stock Sale, the Company and the Investors also entered into a Registration Rights Agreement (the “Investors Registration Rights Agreement”). Pursuant to the Investors Registration Rights Agreement, the Company is required to file a registration statement to cover the resale of the shares of the Common Stock acquired by the investors in the Company Stock Sale. The failure on the part of the Company to satisfy the deadlines set forth in the Investors Registration Rights Agreement may subject the Company to payment of certain monetary penalties. In addition, pursuant to the terms of the Stock Purchase Agreement, the Company has agreed, among other things, not to file any other registration statement (other than any registration statement on Form S-4 or Form S-8, and subject to certain other limitations and exclusions) until the Common Stock subject thereto is covered by an effective registration statement or freely salable under Rule 144 under the Securities Act.

Royalty_Agreement_Note_Payable

Royalty Agreement, Note Payable, and Accrued Interest	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Royalty Agreement, Note Payable, and Accrued Interest	'
	7. Royalty Agreement, Note Payable, and Accrued Interest
	Zogenix
	In August 2006, the Company sold all assets related to its needle-free injector technology platform and products, including 12 U.S. patents along with foreign counterparts, to Zogenix, Inc. In July 2009, Zogenix was granted approval by the U.S. Food and Drug Administration (“FDA”) of the SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system for the treatment of acute migraine and cluster headache. The Company is entitled to quarterly royalty payments of 3% of net sales on all SUMAVEL DosePro sales. The Company recorded royalty revenue of approximately $1.0 million for the twelve months ended December 31, 2013.
	Royalty Financing
	In June 2011, the Company entered into an $8.5 million royalty financing agreement with a syndicate of lenders. The agreement created a debt obligation (the “Term Loan”) that will be repaid through and secured by royalties from net sales of the SUMAVEL DosePro needle-free delivery system payable to the Company under its Asset Purchase Agreement (“APA”) with Zogenix.
	Under the terms of the royalty financing agreement, the Company received a loan of $8.5 million, less fees, transaction and legal expenses (approximately $473,000) and an additional $250,000 set aside for an Interest Reserve Account. The lenders are entitled to receive 100% of all royalties payable to the Company under the APA until the principal and accrued interest of the Term Loan are fully repaid, after which time the benefit of any further royalties made under the APA will accrue to Aradigm. The Term Loan will accrue interest at the rate equal to the greater of a) LIBOR or b) 1.50%, plus a margin of 14.5%. To the extent royalty payments are insufficient to pay accrued and unpaid interest under the financing, the shortfall will be capitalized and added to the principal balance of the Term Loan. During the three months ended March 31, 2012, the Interest Reserve Account was fully utilized and future shortfalls were capitalized and added to the principal balance of the Term Loan. The lenders were granted a security interest in the assets of an Aradigm subsidiary, Aradigm Royalty Financing LLC, which holds Aradigm’s rights to receive royalty payments under the APA. The lenders have no recourse to other assets of Aradigm for repayment of the loan.
	While the term loan is non-recourse to the assets of Aradigm Corporation, the term loan agreement contains a minimum royalty covenant. If the minimum royalty covenant is breached and the subsidiary does not cure the breach through a cash contribution to pay down the accrued principal and interest, then the lenders have the right to declare the agreement in default and obtain the right to all future royalties and payments due to Aradigm under the Zogenix asset purchase agreement. In 2012, the minimum royalty covenant was breached and the Company made a cash payment of approximately $167,000 to the lenders for accrued interest in order to cure the breach. In the twelve months ended December 31, 2013 the covenant was again breached and the cumulative cash shortfall the Company would need to contribute to keep the agreement from default stands at $525,000. The Company has elected not to make this or any future cash contributions and on March 4, 2014, the Company and the other parties executed an assignment agreement that transferred the rights to the lenders, effective as of February 28, 2014, for all future payments from Zogenix under the APA in full and complete satisfaction of the Company’s obligations under the loan agreement and the other agreements entered into in connection with the royalty financing.
	The Company capitalized the fees, transaction and legal expenses of approximately $473,000 and recorded this amount in other assets. The capitalized expenses were to be amortized to interest expense using the effective interest method over a period of 48 months, but the full amount of the remaining capitalized fees and expenses will be recognized in the accounting period following the completion of the transfer of payment rights to the lenders.
	In connection with the transaction, the Company issued to the lenders warrants to purchase a total of 2,840,909 shares of the Company’s common stock at a strike price of $0.22 per share, representing a 20% premium above the average closing price of the Company’s common stock for the ten trading days immediately preceding the closing of the transaction. The warrants expire on December 31, 2016. In accordance with Accounting Standards Topic 815 – Derivatives and Hedging, the warrants were accounted for as equity instruments and their fair value was determined to be approximately $390,000. The relative fair value of the warrants is considered a discount against the note and was recorded as a reduction of the note payable. The note discount is being amortized to interest expense using the effective interest method with an annual rate of 18.7% over a period of 48 months.

Leases_Commitments_and_Conting

Leases, Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Leases, Commitments and Contingencies	'
	8. Leases, Commitments and Contingencies
	The Company has a lease for a building containing offices, laboratory and manufacturing facilities, which expires in 2016. A portion of this lease obligation was offset by a sublease to Mendel Biotechnology, Inc. (“Mendel”). Future minimum non-cancelable lease payments at December 31, 2013 are as follows (in thousands):
		Operating		Mendel			Net Operating
		Leases		Sub-Lease			Lease Payments
	Year ending December 31:
	2014	$	1,844	$	(1,167	)	$	677
	2015		1,917		(1,201	)		716
	2016		1,020		(640	)		380
	Total minimum lease payments	$	4,781	$	(3,008	)	$	1,773
	In July 2007, the Company entered into a sublease agreement with Mendel to lease approximately 48,000 square feet of its 72,000 square foot headquarters located in Hayward, California. In April 2009, the Company entered into an amendment to its sublease agreement with Mendel to sublease an additional 1,550 square feet. In January 2012, the Company entered into a second amendment to the sublease agreement with Mendel to sublease an additional 3,300 square feet during April 2012.
	The sublease commenced in July 2007 and expires concurrently with the master lease in July 2016. Under the sublease and amendments, Mendel will make monthly base rent payments until the end of the term totaling $3.0 million that will offset a portion of the Company’s existing building lease obligation. Under the terms of the second amendment to the sublease entered into in January 2012 Mendel waived their right to early termination. Mendel will also pay the Company for its share of all pass through costs such as taxes, operating expenses and utilities based on the percentage of the facility space occupied by them.
	The Company’s monthly rent payments fluctuate under the master lease. In accordance with U.S. generally accepted accounting principles, the Company recognizes rent expense on a straight-line basis. The Company records deferred rent for the difference between the amounts paid and recorded as expense. At December 31, 2013 and 2012, the Company had $132,000 and $144,000 of deferred rent, respectively.
	For the years ended December 31, 2013 and 2012, building rent expense under operating leases totaled $594,000 and $600,000, respectively.
	Indemnification
	The Company from time to time enters into contracts that contingently require the Company to indemnify parties against third party claims. These contracts primarily relate to: (i) real estate leases, under which the Company may be required to indemnify property owners for environmental and other liabilities, and other claims arising from the Company’s use of the applicable premises, and (ii) agreements with the Company’s officers, directors and employees, under which the Company may be required to indemnify such persons from certain liabilities arising out of such persons’ relationships with the Company. To date, the Company has made no payments related to such indemnifications and no liabilities have been recorded for these obligations on the balance sheets at December 31, 2013 or 2012.
	Legal Matters
	From time to time, the Company is involved in litigation arising out of the ordinary course of its business. Currently there are no known claims or pending litigation expected to have a material effect on the Company’s overall financial position, results of operations, or liquidity.

Shareholders_Equity_Deficit

Shareholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Shareholders' Equity (Deficit)	'
	9. Shareholders’ Equity (Deficit)
	On May 20, 2013, the Company and Grifols and certain other investors (the “Investors”) entered into a Stock Purchase Agreement, pursuant to which the Company agreed, subject to the terms and conditions set forth in the Stock Purchase Agreement, to issue and sell a total of 209,774,558 shares of the Company’s Common Stock, to Grifols and an additional 124,193,546 shares of Common Stock to the Investors, for a total sale of 333,968,104 shares of Common Stock, for a purchase price of $0.124 per share. The aggregate gross consideration paid to the Company in August 2013 in the Company Stock Sale was approximately $41.4 million.
	On December 13, 2012, the Company closed the December 2012 Private Placement. After deducting for fees and expenses, the net proceeds from the sale of the shares of common stock were approximately $5.5 million.
	Reserved Shares
	At December 31, 2013, the Company had 7,766,300 shares reserved for future issuance upon exercise of options under all stock option plans and 40,869,591 shares of common stock reserved for future issuance of new option grants. The Company had 2,688,643 shares available for future issuances under the ESPP. Additionally, the Company had 2,840,909 shares reserved for outstanding warrants at December 31, 2013.
	Shareholder Rights Plan
	In September 2008, the Company adopted an amended and restated shareholder rights plan, which replaced the rights plan originally adopted in August 1998. Pursuant to the rights plan, as amended and restated, the Company distributes rights to purchase shares of Series A Junior Participating Preferred Stock as a dividend at the rate of one right for each share of common stock outstanding. Until the rights are distributed, the rights trade with, and are not separable from, the Company’s common stock and are not exercisable. The rights are designed to guard against partial tender offers and other abusive and coercive tactics that might be used in an attempt to gain control of the Company or to deprive the Company’s shareholders of their interest in the Company’s long-term value. The shareholder rights plan seeks to achieve these goals by encouraging a potential acquirer to negotiate with the Company’s Board of Directors. The rights will expire at the close of business on September 8, 2018.
	Stock Option Plans: 1996 Equity Incentive Plan, 2005 Equity Incentive Plan and 1996 Non-Employee Directors’ Plan
	The 1996 Equity Incentive Plan (the “1996 Plan”) and the 2005 Equity Incentive Plan (the “2005 Plan”), which amended, restated and retitled the 1996 Plan, were adopted to provide a means by which officers, non-employee directors, scientific advisory board members and employees of and consultants to the Company and its affiliates could be given an opportunity to acquire an equity interest in the Company. All officers, non-employee directors, scientific advisory board members and employees of and consultants to the Company are eligible to participate in the 2005 Plan.
	In April 1996, the Company’s Board of Directors adopted and the Company’s shareholders approved the 1996 Plan, which amended and restated an earlier stock option plan. The 1996 Plan reserved 960,000 shares for future grants. During May 2001, the Company’s shareholders approved an amendment to the Plan to include an evergreen provision. In 2003, the 1996 Plan was amended to increase the maximum number of shares available for issuance under the evergreen feature of the 1996 Plan by 400,000 shares to 2,000,000 shares. The evergreen provision automatically increased the number of shares reserved under the 1996 Plan, subject to certain limitations, by 6% of the issued and outstanding shares of common stock of the Company or such lesser number of shares as determined by the Board of Directors on the date of the annual meeting of shareholders of each fiscal year beginning in 2001 and ending 2005. As of December 31, 2013, the Company had 110,000 options outstanding and no shares were available for future grants under the 1996 Plan.
	In March 2005, the Company’s Board of Directors adopted and in May 2005 the Company’s shareholders approved the 2005 Plan, which amended, restated and retitled the 1996 Plan. All outstanding awards granted under the 1996 Plan remain subject to the terms of the 1996 Plan. All stock awards granted on or after the adoption date are subject to the terms of the 2005 Plan. No shares were added to the share reserve under the 2005 Plan other than the shares available for future issuance under the 1996 Plan. Pursuant to the 2005 Plan, the Company had 2,918,638 shares of common stock authorized for issuance. Options (net of canceled or expired options) covering an aggregate of 1,999,252 shares of the Company’s common stock had been granted under the 1996 Plan, and 919,386 shares became available for future grant under the 2005 Plan. In March 2006, the Company’s Board of Directors amended, and in May 2006 the Company’s shareholders approved, the amendment to the 2005 Plan, increasing the shares of common stock authorized for issuance by 2,000,000. In April 2007, the Company’s Board of Directors amended, and in June 2007, the Company’s shareholders approved the amendment to the 2005 Plan, increasing the shares of common stock authorized for issuance by 1,600,000 shares. In March 2008, the Company’s Board of Directors amended, and in May 2008 the Company shareholder’s approved, the amendment to the 2005 Plan, increasing the shares of common stock authorized by 2,700,000. In March 2010, the Company’s Board of Directors amended, and in May 2010, the Company shareholder’s approved the amendment to the 2005 Plan, increasing the shares of common stock authorized by 4,000,000. In March 2012, the Company’s Board of Directors amended, and in May 2012, the Company shareholder’s approved the amendment to the 2005 Plan, increasing the shares of common stock authorized by 4,000,000. In May of 2013, the Company’s Board of Directors amended, and in July 2013, the Company’s shareholder’s approved the amendment to the 2005 Plan, increasing the shares of common stock authorized by 40,000,000. Shares available for future grants totaled 40,869,591 as of December 31, 2013 for the 2005 Plan.
	Options granted under the 2005 Plan expire no later than 10 years from the date of grant. Options granted under the 2005 Plan may be either incentive or non-statutory stock options. For incentive and non-statutory stock option grants, the option price shall be at least 100% and 85%, respectively, of the fair value on the date of grant, as determined by the Company’s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110% of the fair value and shall not be exercisable more than five years after the date of grant.
	Options granted under the 2005 Plan may be immediately exercisable if permitted in the specific grant approved by the Board of Directors and, if exercised early may be subject to repurchase provisions. The shares acquired generally vest over a period of four years from the date of grant. The 2005 Plan also provides for a transition from employee to consultant status without termination of the vesting period as a result of such transition. Under the 2005 Plan, employees may exercise options in exchange for a note payable to the Company, if permitted under the applicable grant. As of December 31, 2013 and 2012, there were no outstanding notes receivable from shareholders. Any unvested stock issued is subject to repurchase agreements whereby the Company has the option to repurchase unvested shares upon termination of employment at the original issue price. The common stock subject to repurchase has voting rights, but cannot be resold prior to vesting. No grants with early exercise provisions have been made under the 2005 Plan and no shares have been repurchased. The Company granted options to purchase 1,170,000 shares and 560,000 shares during the years ended December 31, 2013 and 2012, respectively, under the 2005 Plan, which included option grants to the Company’s non-employee directors in the amount of 670,000 shares and 560,000 shares during 2013 and 2012, respectively. The 2005 Plan had 7,656,300 option shares outstanding as of December 31, 2013.
	The 1996 Non-Employee Directors’ Stock Option Plan (the “Directors’ Plan”) had 45,000 shares of common stock authorized for issuance. Options granted under the Directors’ Plan expire no later than 10 years from date of grant. The option price shall be at 100% of the fair value on the date of grant as determined by the Board of Directors. The options generally vest quarterly over a period of one year. During 2000, the Board of Directors approved the termination of the Directors’ Plan. No more options can be granted under the plan after its termination. The termination of the Directors’ Plan had no effect on the options already outstanding. As of December 31, 2013, there were no outstanding options in this plan and there were no additional shares available for grant.
	The following is a summary of activity under the 1996 Plan, the 2005 Plan and the Directors’ Plan as of December 31, 2013:
					Options Outstanding
		Shares Available			Number of			Price per Share						Weighted
		for Grant of			Shares									Average
		Option or Award												Exercise
														Price
	Balance at December 31, 2011		750,133			6,843,508		$	0.12		—	$	24.1	$	1.05
	Options granted		(560,000	)		560,000		$	0.15		—	$	0.15	$	0.15
	Increase in authorized shares		4,000,000			—		$	—		—	$	—	$	—
	Options cancelled		648,308			(648,308	)	$	0.13		—	$	24.1	$	2.52
	Restricted stock awards granted		(1,884,417	)		—		$	—		—	$	—	$	—
	Balance at December 31, 2012		2,954,024			6,755,200		$	0.12		—	$	12	$	0.83
	Options granted		(1,170,000	)		1,170,000		$	0.12		—	$	0.2	$	0.16
	Increase in authorized shares		40,000,000			—			—				—		—
	Options cancelled		148,900			(148,900	)	$	0.15		—	$	10.8	$	1.92
	Options exercised		—			(10,000	)	$	0.16		—	$	0.16	$	0.16
	Restricted stock awards granted		(1,213,333	)		—		$	—		—	$	—	$	—
	Restricted stock awards cancelled		150,000			—		$	—		—	$	—	$	—
	Balance at December 31, 2013		40,869,591			7,766,300		$	0.12		—	$	12	$	0.71
	The following table summarizes information about stock options outstanding and exercisable as of December 31, 2013:
		Options Outstanding								Options Exercisable
					Weighted
					Average			Weighted				Weighted
		Number			Remaining			Average				Average
		Of			Contractual			Exercise		Number of		Exercise
	Exercise Price Range	Shares			Life (In Years)			Price		Shares		Price
	$0.12 - $0.13		370,000			6.9		$	0.12		355,000	$	0.12
	$0.15 - $0.15		1,071,000			7.69			0.15		861,000		0.15
	$0.16 - $0.17		1,233,000			7.5			0.17		733,000		0.16
	$0.18 - $0.18		1,344,000			6			0.18		1,344,000		0.18
	$0.19- $0.25		1,211,500			5.41			0.23		1,199,000		0.23
	$0.39- $1.60		1,347,800			3.89			1.26		1,347,800		1.26
	$1.64- $1.87		999,000			2.57			1.8		999,000		1.8
	$3.14 - $6.90		156,000			1.39			4.77		156,000		4.77
	$7.95 - $7.95		12,000			1.07			7.95		12,000		7.95
	$12.00 - $12.00		22,000			0.16			12		22,000		12
			7,766,300			5.5		$	0.71		7,028,800	$	0.77
	Aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the stock options at December 31, 2013 and 2012 for those stock options for which the quoted market price was in excess of the exercise price (“in-the-money options”). As of December 31, 2013 and 2012, the aggregate intrinsic value of options outstanding was $45,000 and $3,000, respectively. As of December 31, 2013, options to purchase 7,028,200 shares of common stock were exercisable and had an aggregate intrinsic value of $40,000. Ten thousand stock options were exercised in 2013 and none were exercised in 2012.
	A summary of the activity of the Company’s unvested restricted stock and performance bonus stock award activities for the years ending December 31, 2013 and 2012 is presented below. The ending balances represent the maximum number of shares that could be earned or vested under the 2005 Plan:
		Number of			Weighted Average
		Shares			Grant Date Fair Value
	Balance at December 31, 2011		938,976			0.19
	Restricted stock awards granted		1,884,417			0.14
	Restricted share awards vested		(1,370,309	)		0.16
	Balance at December 31, 2012		1,453,084			0.14
	Restricted stock awards granted		1,213,333			0.16
	Restricted stock awards cancelled		(150,000	)		0.15
	Restricted share awards vested		(1,747,750	)		0.14
	Balance at December 31, 2013		768,667			0.18
For restricted stock awards, the Company recognizes compensation expense over the vesting period for the fair value of the stock award on the measurement date. The total fair value of restricted stock awards that did vest during the years ended December 31, 2013 and 2012 was $307,000 and $185,000, respectively. The Company retained purchase rights to 769,000 and 1,453,000 shares of unvested restricted stock awards issued pursuant to stock purchase agreements at no cost per share as of December 31, 2013 and 2012, respectively. Total employee stock-based compensation expense for restricted stock awards was $215,000 and $236,000 for the years ended December 31, 2013 and 2012, respectively.
During the year ended December 31, 2011, the Company issued 78,947 shares of restricted stock units with no exercise price to non-employee members of its Board of Directors. The units will vest on the earlier of either a change in control of the Company or upon the grantee’s termination of service as a Board member. In both 2013 and 2012, the non-employee members of the Board of Directors elected to forego all or a portion of their cash compensation in exchange for the aforementioned restricted stock unit grants and restricted stock awards.
Employee Stock Purchase Plan
Employees generally are eligible to participate in the ESPP if they have been continuously employed by the Company for at least 10 days prior to the first day of the offering period and are customarily employed at least 20 hours per week and at least five months per calendar year and are not a 5% or greater shareholder. Shares may be purchased under the ESPP at 85% of the lesser of the fair market value of the common stock on the grant date or purchase date. Employee contributions, through payroll deductions, are limited to the lesser of 15% of earnings or $25,000.
As of December 31, 2013, a total of 4,361,357 shares had been issued under the ESPP. In April 2008, the Company’s Board of Directors amended, and in May 2008 the Company’s shareholder approved, the amendment to the ESPP increasing the shares of common stock authorized by 1,000,000. In April 2009, the Company’s Board of Directors amended, and in May 2009 the Company’s shareholders approved, the amendment to the ESPP increasing the number of shares of common stock authorized by 2,500,000. In March 2013, the Company’s Board of Directors amended, and in May 2013 the Company’s shareholders approved, the amendment to the ESPP increasing the number of shares of common stock authorized by 2,500,000. As of December 31, 2013, there was a balance of 2,688,643 available authorized shares. Compensation expense was $106,000 and $57,000 for the years ended December 31, 2013 and 2012, respectively. The fair value of employee stock purchase rights under the ESPP is determined using the Black-Scholes option pricing model and the following weighted average assumptions:
	Years Ended December 31,
	2013			2012
Employee Stock Purchase Plan
Dividend yield		0	%		0	%
Volatility factor		245.1	%		105.3	%
Risk-free interest rate		0.2	%		1	%
Expected life (years)		2			2
Weighted-average fair value of purchase rights granted during the period	$	0.14		$	0.12
Stock-Based Compensation Expense
The Company recognizes stock-based compensation expense based on the fair value of that portion of stock options and restricted stock awards that are ultimately expected to vest during the period. Stock-based compensation expense recognized in the Consolidated Statement of Operations and Comprehensive Loss includes compensation expense for stock-based awards based on the estimated grant date fair value over the requisite service period.
The following table shows stock-based compensation expense included in the consolidated statement of operations and comprehensive loss for the years ended December 31, 2013 and 2012, (in thousands, except per share amounts):
	2013			2012
Costs and Expenses
Research and development	$	138		$	102
General and administrative		283			371
Total employee stock-based compensation expense	$	421		$	473
Impact on basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)
There was no capitalized stock-based compensation cost as of December 31, 2013. Since the Company has cumulative net losses through December 31, 2013, there was no tax benefit associated with stock-based compensation expense.
The total amount of unrecognized compensation cost related to unvested stock options and stock purchases net of forfeitures was $88,000 as of December 31, 2013. This amount will be recognized over a weighted average period of 2.76 years. As of December 31, 2013, $106,000 of total unrecognized compensation costs, net of forfeitures, related to unvested awards is expected to be recognized over a weighted average period of 0.32 years.
Valuation Assumptions
The fair value of options was estimated at the date of grant using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock for similar terms. The expected term was estimated using a lattice model prior to 2010, and the simplified method was used starting in 2010 as permitted under SAB No. 110, since the Company’s recent exercise and forfeiture history was not representative of the expected term of options granted during the year. The expected term represents the estimated period of time that stock options are expected to be outstanding, which is less than the contractual term which is generally ten years. The risk-free interest rate is based on the U.S. Treasury yield. The expected dividend yield is zero, as the Company does not anticipate paying dividends in the near future. The weighted average assumptions for employee and non-employee options are as follows:
	Years Ended December 31
	2013			2012
Dividend yield		0	%		0	%
Volatility factor		173	%		172	%
Risk-free interest rate		1.4	%		0.8	%
Expected term (years)		5.7			5.3
Weighted-average fair value of options granted during the periods	$	0.15		$	0.14
Stock-Based Compensation for Non-Employees
The Company accounts for options issued to non-employees under ASC 505-50, Equity – Equity Based Payments to Non-Employees, using the Black-Scholes option-pricing model. The value of such non-employee options are periodically re-measured over their vesting terms.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	10. Employee Benefit Plans
	The Company provides a 401(k) Plan for all full-time employees. Employees can contribute on a pretax basis up to the 2013 statutory limit of $17,500 (plus an additional $5,500 for employees that are 50 years and older). The Company matches employees’ contributions up to a maximum of three percent of an employee’s annual salary based upon the employee’s contribution and certain other limitations. The Company’s employer matching contribution expense was $40,000 and $10,000 in 2013 and 2012, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	11. Income Taxes
	In 2013 and 2012, the Company recorded an income tax benefit of zero. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for tax purposes as well as net operating loss and tax credit carryforwards.
	Significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands):
		December 31,
		2013			2012
	Net operating loss carryforwards	$	16,739		$	14,332
	Research and development credits		6,509			6,509
	Federal orphan drug credits		7,228			7,228
	Other		1,210			1,881
	Total deferred tax assets		31,686			29,950
	Valuation allowance		(31,686	)		(29,950	)
	Net deferred tax assets	$	—		$	—
	The Company considers all available evidence, both positive and negative, including historical levels of taxable income, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. At December 31, 2013 and 2012, based on the Company’s analysis of all available evidence, both positive and negative, it was considered more likely than not that the Company’s deferred tax assets would not be realized, and as a result, the Company recorded a valuation allowance for its deferred tax assets. The valuation allowance increased by $1.7 million during the year ended December 31, 2013 and increased by $5.0 million during the year ended December 31, 2012. In accordance with ASC 718 Compensation-Stock Compensation, the Company has excluded from deferred tax assets those tax benefits attributable to employee stock option exercises.
	The difference between the income tax benefit and the amount computed by applying the federal statutory income tax rate to loss before income taxes is as follows (in thousands):
		Year Ended December 31,
		2013			2012
	Income tax benefit at federal statutory rate	$	(7,544	)	$	(2,878	)
	State taxes (net of federal)		186			(648	)
	Credits		—			(662	)
	Other		43			(842	)
	Collaboration arrangement acquisition cost		5,580			—
	Change in valuation allowance		1,735			5,030
	Total	$	—		$	—
	As of December 31, 2013, the Company had federal net operating loss carryforwards of approximately 41.2 million and federal orphan drug credit carryforwards of approximately $7.2 million, which expire in the years 2019 through 2032. The Company also had California net operating loss carryforwards of approximately $40.1 million, which expire in the years 2014 through 2033, and California research and development tax credit carryforwards of approximately $10.0 million, which do not expire. None of the federal and state net operating loss carryforwards represent stock option deductions arising from activity under the Company’s stock option plan.
	The Company’s federal and state net operating loss (NOL’s) and tax credit carryforwards are subject to substantial annual limitations as a result of certain ownership changes that occurred in 2010 and prior years. Federal net operating loss (NOL) carryforwards totaling $41.2 million will begin to expire from 2019 to 2033, subject to the annual limitations. Federal tax credit carryforwards totaling $7.3 million will begin to expire from 2028 to 2032, subject to the annual limitations. State operating loss carryforwards totaling $40.1 million will begin to expire from 2014 to 2033, subject to annual limitations. State tax credit carryforwards may be subject to further annual limitations for ownership changes occurring after December 31, 2013.
	Utilization of the Company’s NOL and credit carryforwards may be subject to additional annual limitations based on future stock issuances or ownership changes. Such future limitations could result in the expiration of the net operating loss and credit carryforwards before utilization. Based on the analyses performed on ownership changes that have occurred from inception through December 31, 2013, the Company expects to be able to use the NOL and tax credit carryforwards as noted above.
	The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company is subject to U.S. federal and state income tax examinations by tax authorities for tax years from 1998 due to net operating losses and tax credits that are being carried forward for tax purposes.
	The Company does not have any unrecognized tax benefits, or interest and penalties accrued on unrecognized tax benefits, at December 31, 2013, or during the two years then ended. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

Quarterly_Results_of_Operation

Quarterly Results of Operations	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Results of Operations	'
	12. Quarterly Results of Operations (unaudited)
	Following is a summary of the quarterly results of operations for the years ended December 31, 2013 and 2012 (in thousands, except per share amounts):
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Total revenue	$	279		$	248		$	4,552		$	4,638
	Operating expenses:
	Research and development		1,984			1,423			1,593			3,884
	General and administrative		1,220			1,118			1,463			974
	Collaboration arrangement acquisition cost		—			—			15,943			—
	Restructuring and asset impairment		7			7			7			6
	Total expenses		3,211			2,548			19,006			4,864
	Loss from operations		(2,932	)		(2,300	)		(14,454	)		(226	)
	Interest expense, net		(392	)		(406	)		(420	)		(425	)
	Other expense		(1	)		(4	)		—			(4	)
	Loss before income taxes		(3,325	)		(2,710	)		(14,874	)		(655	)
	Income tax provision		—			—			—			—
	Net loss	$	(3,325	)	$	(2,710	)	$	(14,874	)	$	(655	)
	Basic and diluted net loss per common share	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.00	)
	Shares used in computing basic and diluted net loss per common share		249,941			250,417			374,126			586,391
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Total revenues	$	282		$	240		$	262		$	223
	Operating expenses:
	Research and development		786			700			818			1,477
	General and administrative		1,083			913			1,013			887
	Restructuring and asset impairment		9			9			8			8
	Total expenses		1,878			1,622			1,839			2,372
	Loss from operations		(1,596	)		(1,382	)		(1,577	)		(2,149	)
	Interest expense, net		(366	)		(379	)		(381	)		(394	)
	Other income (expense)		2			—			(4	)		—
	Loss before income taxes		(1,960	)		(1,761	)		(1,962	)		(2,543	)
	Income tax provision		(1	)		—			—			—
	Net loss	$	(1,961	)	$	(1,761	)	$	(1,962	)	$	(2,543	)
	Basic and diluted net loss per common share	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)
	Shares used in computing basic and diluted net loss per common share		197,923			198,406			198,670			201,137

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	13. Subsequent Events
	The Company has evaluated subsequent events that have occurred after December 31, 2013 and determined that there were no events or transactions occurring during this reporting period which require recognition or disclosure in the financial statements other than as discussed in Note 7.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization	'
	Organization
	Aradigm Corporation (the “Company”) is a California corporation, incorporated in 1991, focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The Company’s principal activities to date have included conducting research and development and developing collaborations. Management does not anticipate receiving revenues from the sale of any of its products in the upcoming year. The Company operates as a single operating segment.
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All inter-company accounts and transactions have been eliminated in consolidation.
Liquidity and Financial Condition	'
	Liquidity and Financial Condition
	The Company has incurred significant operating losses and negative cash flows from operations. At December 31, 2013, the Company had an accumulated deficit of $392.9 million, working capital of $42.4 million and shareholders’ equity of $33.7 million. The Company believes that its cash and cash equivalents totaling $48.1 million as of December 31, 2013 will be sufficient to fund its operations at least through 2014. However, the Company’s business strategy may require it to , or it may otherwise determine to, raise additional capital at any time through equity financing(s), strategic transactions or otherwise. Such additional funding may be necessary to develop the Company’s potential product candidates. In addition, the Company may determine to raise capital opportunistically.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements, in conformity with United States generally accepted accounting principles, requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, and income taxes. Actual results could differ from these estimates.
Cash Equivalents	'
	Cash Equivalents
	All highly liquid investments with maturities of three months or less at the time of purchase are classified as cash equivalents.
Investments	'
	Investments
	Management determines the appropriate classification of the Company’s marketable securities, which consist solely of debt securities, at the time of purchase. All marketable securities are classified as available-for-sale, carried at estimated fair value and reported in short-term investments. Unrealized gains and losses on available-for-sale securities are excluded from earnings and losses and are reported as a separate component in the statement of shareholders’ equity (deficit) until realized. Fair values of investments are based on quoted market prices where available. Investment income is recognized when earned and includes interest, dividends, amortization of purchase premiums and discounts and realized gains and losses on sales of securities. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. When the Company determines that the decline in fair value of an investment below the Company’s accounting basis is other-than-temporary, the Company reduces the carrying value of the securities held and records a loss in the amount of any such decline. No such reductions have been required during any of the periods presented.
Property and Equipment	'
	Property and Equipment
	The Company records property and equipment at cost and calculates depreciation using the straight-line method over the estimated useful lives of the respective assets. Machinery and equipment includes external costs incurred for validation of the equipment. The Company does not capitalize internal validation expense. Computer equipment and software includes capitalized computer software. All of the Company’s capitalized software is purchased; the Company has no internally developed computer software. Leasehold improvements are depreciated over the shorter of the term of the lease or useful life of the improvement.
	The estimated useful lives of property and equipment are as follows:
	Computer equipment and software	3 to 5 years
	Furniture and fixtures	5 to 7 years
	Lab equipment	5 to 7 years
	Machinery and equipment	5 years
	Leasehold improvements	5 to 17 years
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company reviews for impairment whenever events or changes in circumstances indicate that the carrying amount of property and equipment may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values and the loss is recognized in the consolidated statements of operations.
Accounting for Costs Associated with Exit or Disposal Activities	'
	Accounting for Costs Associated with Exit or Disposal Activities
	The Company recognizes a liability for the cost associated with an exit or disposal activity that is measured initially at its fair value in the period in which the liability is incurred. The Company accounted for the partial sublease of its headquarters building as an exit activity and recorded the sublease loss in its statement of operations and comprehensive net loss (see Note 5).
	Costs to terminate an operating lease or other contracts are (a) costs to terminate the contract before the end of its term or (b) costs that will continue to be incurred under the contract for its remaining term without economic benefit to the entity. In periods subsequent to initial measurement, changes to the liability are measured using the credit adjusted risk-free rate that was used to measure the liability initially.
Revenue Recognition	'
	Revenue Recognition
	Contract revenues consist of revenues from grants, collaboration agreements and feasibility studies. License and collaboration revenue is primarily generated through agreements with strategic partners for the development and commercialization of our product candidates. The terms of the agreement typically include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones and royalties on net product sales. The Company recognizes revenue under the provisions of the Securities and Exchange Commission issued Staff Accounting Bulletin 104, Topic 13, Revenue Recognition Revised and Updated (“SAB Topic 13”) and ASC 605-25, Revenue Recognition-Multiple Elements. Revenue for arrangements not having multiple deliverables, as outlined in ASC 605-25, is recognized once costs are incurred and collectability is reasonably assured.
	Revenue is recognized when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed and determinable and collection is reasonably assured. Multiple-deliverable arrangements, such as license and development agreements, are analyzed to determine whether the deliverables can be separated or whether they must be accounted for as a single unit of accounting. When deliverables are separable, consideration received is allocated to the separate units of accounting based on the relative selling price method and the appropriate revenue recognition principles are applied to each unit. When the Company determines that an arrangement should be accounted for as a single unit of accounting, it must determine the period over which the performance obligations will be performed and revenue will be recognized.
	The Company estimates its performance period used for revenue recognition based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances. Significant management judgment may be required to determine the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.
	The Company prospectively adopted the provisions of Accounting Standards Update No. 2009-13, Revenue Recognition (Topic 605); Multiple-Deliverable Revenue Arrangements (“ASU 2009-13”) for new and materially modified arrangements originating on or after January 1, 2010. ASU 2009-13 provides updated guidance on how the deliverables in an arrangement should be separated, and how consideration should be allocated, and it changes the level of evidence of standalone selling price required to separate deliverables by allowing a vendor to make its best estimate of the standalone selling price of deliverables when vendor-specific objective evidence or third-party evidence of selling price is not available.
	The Company allocates non-contingent consideration to each stand-alone deliverable based upon the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using vendor-specific objective evidence, or VSOE, of selling price, if it exists, or third-party evidence, or TPE, of selling price, if it exists. If neither VSOE nor TPE of selling price exist for a deliverable, the Company uses best estimated selling price, or BESP, for that deliverable.
	Assuming the elements meet the revenue recognition guidelines, the revenue recognition methodology prescribed for each unit of accounting is summarized below:
	Upfront Fees—The Company defers recognition of non-refundable upfront fees if there are continuing performance obligations without which the technology licensed has no utility to the licensee. If the Company has continuing performance obligations through research and development services that are required because know-how and expertise related to the technology is proprietary to the Company, or can only be performed by the Company, then such up-front fees are deferred and recognized over the estimated period of the performance obligation. The Company bases the estimate of the period of performance on factors in the contract. Actual time frames could vary and could result in material changes to the results of operations. When the collaboration partners request the Company to continue performing the research and development services in collaboration beyond the initial period of performance the remaining unamortized deferred revenue and any new continuation or license fees are recognized over the extended period of performance.
	Funded Research and Development—Revenue from research and development services is recognized during the period in which the services are performed and is based upon the number of full-time-equivalent personnel working on the specific project at the agreed-upon rate. The full-time equivalent amount can vary each year if the contracts allow for a percentage increase determined by relevant salary surveys, if applicable. Reimbursements from collaborative partners for agreed upon direct costs including direct materials and outsourced, or subcontracted, pre-clinical studies are classified as revenue and recognized in the period the reimbursable expenses are incurred. Payments received in advance are recorded as deferred revenue until the research and development services are performed or costs are incurred.
	Milestones—Substantive milestone payments are considered to be performance bonuses that are recognized upon achievement of the milestone only if all of the following conditions are met: the milestone payments are non-refundable; achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; substantive effort is involved in achieving the milestone; the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and a reasonable amount of time passes between the up-front license payment and the first milestone payment as well as between each subsequent milestone payment. If any of these conditions are not met, the milestone payments are deferred and recognized as revenue over the term of the arrangement as the Company completes its performance obligations.
	Royalties—The Company recognizes royalty revenues from licensed products upon the sale of the related products.
Research and Development	'
	Research and Development
	Research and development expenses consist of costs incurred for company-sponsored, collaborative and contracted research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs as such costs are incurred.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for share-based payment arrangements in accordance with ASC 718, Compensation-Stock Compensation and ASC 505-50, Equity-Equity Based Payments to Non-Employees which requires the recognition of compensation expense, using a fair-value based method, for all costs related to share-based payments including stock options and restricted stock awards and stock issued under the Employee Stock Purchase Plan (“ESPP”). These standards require companies to estimate the fair value of share-based payment awards on the date of the grant using an option-pricing model. See Note 9 for further discussion of the Company’s stock-based compensation plans.
Income Taxes	'
	Income Taxes
	The Company makes certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of the recognition of revenue and expense for tax and financial statement purposes. As part of the process of preparing the financial statements, the Company is required to estimate its income taxes in each of the jurisdictions in which it operates. This process involves the estimation of the current tax exposure under the most recent tax laws and assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities which are included in the Company’s consolidated balance sheets.
	The Company assesses the likelihood that it will be able to recover its deferred tax assets. The Company considers all available evidence, both positive and negative, including its historical levels of income and losses, expectations and risks associated with estimates of future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance. If the Company does not consider it more likely than not that it will recover its deferred tax assets, it will record a valuation allowance against the deferred tax assets that it estimates will not ultimately be recoverable. At December 31, 2013 and 2012, the Company believed that the amount of its deferred income taxes would not be ultimately recovered. Accordingly, the Company recorded a full valuation allowance for deferred tax assets. However, should there be a change in the Company’s ability to recover its deferred tax assets, it would recognize a benefit to its tax provision in the period in which it determines that it is more likely than not that it will recover its deferred tax assets.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic net loss per common share is computed using the weighted-average number of shares of common stock outstanding less the weighted-average number of shares subject to repurchase. Unvested restricted stock awards subject to repurchase totaled 769,000 shares and 1,453,000 shares for the years ended December 31, 2013 and 2012, respectively. Potentially dilutive securities were not included in the net loss per share calculation for the years ended December 31, 2013 and 2012 because the inclusion of such shares would have had an anti-dilutive effect.
	Potentially dilutive securities include the following (in thousands):
		Years Ended December 31,
		2013		2012
	Outstanding stock options		7,766		6,755
	Unvested restricted stock awards		769		1,453
	Outstanding warrants		2,841		2,841
Significant Concentrations	'
	Significant Concentrations
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents and short-term investments. Risks associated with these instruments are mitigated by banking with, and only purchasing commercial paper and corporate notes from, creditworthy institutions. The maximum amount of loss due to credit risk associated with these financial instruments is their respective fair values as stated in the accompanying Consolidated Balance Sheets.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	ASC 220, Comprehensive Income requires that an entity’s change in equity or net assets during a period from transactions and other events from non-owner sources be reported. The Company reports unrealized gains or losses on its available-for-sale securities as other comprehensive income (loss). Total comprehensive income (loss) has been disclosed on the Consolidated Statement of Operations and Comprehensive Loss.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	There have been no recent accounting pronouncements or changes in accounting pronouncements during the year ended December 31, 2013 that are of significance, or potential significance to the Company.

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Property and Equipment	'
	The estimated useful lives of property and equipment are as follows:
	Computer equipment and software	3 to 5 years
	Furniture and fixtures	5 to 7 years
	Lab equipment	5 to 7 years
	Machinery and equipment	5 years
	Leasehold improvements	5 to 17 years
Property and Equipment [Member]	'
Schedule of Property and Equipment	'
	Property and equipment consist of the following (in thousands):
		December 31,
		2013			2012
	Machinery and equipment	$	4,412		$	4,385
	Furniture and fixtures		1,138			1,138
	Lab equipment		2,138			2,138
	Computer equipment and software		2,651			2,640
	Leasehold improvements		1,844			1,839
	Property and equipment		12,183			12,140
	Less accumulated depreciation and amortization		(11,783	)		(11,413	)
	Property and equipment, net	$	400		$	727

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Potentially Dilutive Securities	'
	Potentially dilutive securities include the following (in thousands):
		Years Ended December 31,
		2013		2012
	Outstanding stock options		7,766		6,755
	Unvested restricted stock awards		769		1,453
	Outstanding warrants		2,841		2,841

Cash_Cash_Equivalents_and_Shor1

Cash, Cash Equivalents and Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Cash And Cash Equivalents [Abstract]	'
Summary of Cash and Cash Equivalents and Short-term Investments	'
	A summary of cash and cash equivalents and short-term investments, classified as available-for-sale and carried at fair value is as follows (in thousands):
		Amortized		Gross		Gross		Estimated
		Cost		Unrealized		Unrealized		Fair Value
				Gain		(Loss)
	December 31, 2013
	Cash and cash equivalents	$	48,131	$	—	$	—	$	48,131
	December 31, 2012
	Cash and cash equivalents	$	7,414	$	—	$	—	$	7,414
	Short-term investments:
	U.S. Treasury notes	$	203		—		—	$	203
	Total	$	7,617	$	—	$	—	$	7,617

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Summary of Assets Measured at Fair Value on Recurring Basis	'
	The following table presents the fair value level for the cash and cash equivalents and short-term investments which represents the assets that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. The Company does not have any liabilities that are measured at fair value.
	Description	Balance		Level 1		Level 2		Level 3
		December 31,
		2013
		(In thousands)
	Cash and cash equivalents	$	48,131	$	48,131	$	—	$	—

Sublease_Agreement_and_Lease_E1

Sublease Agreement and Lease Exit Liability (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring And Related Activities [Abstract]	'
Schedule of Lease Exit Liability Activity	'
	The lease exit liability activity for the years ended December 31, 2013 and 2012 are as follows (in thousands):
		Year Ended December 31,
		2013			2012
	Balance at beginning of year	$	609		$	729
	Accretion expense		26			34
	Lease payments		(170	)		(154	)
	Balance at end of the year	$	465		$	609

Leases_Commitments_and_Conting1

Leases, Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Future Minimum Non-Cancelable Lease Payments	'
	Future minimum non-cancelable lease payments at December 31, 2013 are as follows (in thousands):
		Operating		Mendel			Net Operating
		Leases		Sub-Lease			Lease Payments
	Year ending December 31:
	2014	$	1,844	$	(1,167	)	$	677
	2015		1,917		(1,201	)		716
	2016		1,020		(640	)		380
	Total minimum lease payments	$	4,781	$	(3,008	)	$	1,773

Shareholders_Equity_Deficit_Ta

Shareholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of Share Based Compensation Activity	'
	The following is a summary of activity under the 1996 Plan, the 2005 Plan and the Directors’ Plan as of December 31, 2013:
					Options Outstanding
		Shares Available			Number of			Price per Share						Weighted
		for Grant of			Shares									Average
		Option or Award												Exercise
														Price
	Balance at December 31, 2011		750,133			6,843,508		$	0.12		—	$	24.1	$	1.05
	Options granted		(560,000	)		560,000		$	0.15		—	$	0.15	$	0.15
	Increase in authorized shares		4,000,000			—		$	—		—	$	—	$	—
	Options cancelled		648,308			(648,308	)	$	0.13		—	$	24.1	$	2.52
	Restricted stock awards granted		(1,884,417	)		—		$	—		—	$	—	$	—
	Balance at December 31, 2012		2,954,024			6,755,200		$	0.12		—	$	12	$	0.83
	Options granted		(1,170,000	)		1,170,000		$	0.12		—	$	0.2	$	0.16
	Increase in authorized shares		40,000,000			—			—				—		—
	Options cancelled		148,900			(148,900	)	$	0.15		—	$	10.8	$	1.92
	Options exercised		—			(10,000	)	$	0.16		—	$	0.16	$	0.16
	Restricted stock awards granted		(1,213,333	)		—		$	—		—	$	—	$	—
	Restricted stock awards cancelled		150,000			—		$	—		—	$	—	$	—
	Balance at December 31, 2013		40,869,591			7,766,300		$	0.12		—	$	12	$	0.71
Summary of Stock Options Outstanding and Exercisable	'
	The following table summarizes information about stock options outstanding and exercisable as of December 31, 2013:
		Options Outstanding								Options Exercisable
					Weighted
					Average			Weighted				Weighted
		Number			Remaining			Average				Average
		Of			Contractual			Exercise		Number of		Exercise
	Exercise Price Range	Shares			Life (In Years)			Price		Shares		Price
	$0.12 - $0.13		370,000			6.9		$	0.12		355,000	$	0.12
	$0.15 - $0.15		1,071,000			7.69			0.15		861,000		0.15
	$0.16 - $0.17		1,233,000			7.5			0.17		733,000		0.16
	$0.18 - $0.18		1,344,000			6			0.18		1,344,000		0.18
	$0.19 - $0.25		1,211,500			5.41			0.23		1,199,000		0.23
	$0.39 - $1.60		1,347,800			3.89			1.26		1,347,800		1.26
	$1.64 - $1.87		999,000			2.57			1.8		999,000		1.8
	$3.14 - $6.90		156,000			1.39			4.77		156,000		4.77
	$7.95 - $7.95		12,000			1.07			7.95		12,000		7.95
	$12.00 - $12.00		22,000			0.16			12		22,000		12
			7,766,300			5.5		$	0.71		7,028,800	$	0.77
Schedule of Unvested Restricted Stock and Performance Bonus Stock Award	'
	A summary of the activity of the Company’s unvested restricted stock and performance bonus stock award activities for the years ending December 31, 2013 and 2012 is presented below. The ending balances represent the maximum number of shares that could be earned or vested under the 2005 Plan:
		Number of			Weighted Average
		Shares			Grant Date Fair Value
	Balance at December 31, 2011		938,976			0.19
	Restricted stock awards granted		1,884,417			0.14
	Restricted share awards vested		(1,370,309	)		0.16
	Balance at December 31, 2012		1,453,084			0.14
	Restricted stock awards granted		1,213,333			0.16
	Restricted stock awards cancelled		(150,000	)		0.15
	Restricted share awards vested		(1,747,750	)		0.14
	Balance at December 31, 2013		768,667			0.18
Employee Stock Purchase Plan	'
	The fair value of employee stock purchase rights under the ESPP is determined using the Black-Scholes option pricing model and the following weighted average assumptions:
		Years Ended December 31,
		2013			2012
	Employee Stock Purchase Plan
	Dividend yield		0	%		0	%
	Volatility factor		245.1	%		105.3	%
	Risk-free interest rate		0.2	%		1	%
	Expected life (years)		2			2
	Weighted-average fair value of purchase rights granted during the period	$	0.14		$	0.12
Schedule of Stock Based Compensation Expenses	'
	The following table shows stock-based compensation expense included in the consolidated statement of operations and comprehensive loss for the years ended December 31, 2013 and 2012, (in thousands, except per share amounts):
		2013			2012
	Costs and Expenses
	Research and development	$	138		$	102
	General and administrative		283			371
	Total employee stock-based compensation expense	$	421		$	473
	Impact on basic and diluted net loss per common share	$	(0.00	)	$	(0.00	)
Schedule of Stock Based Compensation Valuation Assumption	'
	The weighted average assumptions for employee and non-employee options are as follows:
		Years Ended December 31
		2013			2012
	Dividend yield		0	%		0	%
	Volatility factor		173	%		172	%
	Risk-free interest rate		1.4	%		0.8	%
	Expected term (years)		5.7			5.3
	Weighted-average fair value of options granted during the periods	$	0.15		$	0.14

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Significant Components of Company's Deferred Tax Assets and Liabilities	'
	Significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands):
		December 31,
		2013			2012
	Net operating loss carryforwards	$	16,739		$	14,332
	Research and development credits		6,509			6,509
	Federal orphan drug credits		7,228			7,228
	Other		1,210			1,881
	Total deferred tax assets		31,686			29,950
	Valuation allowance		(31,686	)		(29,950	)
	Net deferred tax assets	$	—		$	—
Schedule of Difference Between Income Tax Benefit and Computation Amount of Federal Statutory Income Tax Rate	'
	The difference between the income tax benefit and the amount computed by applying the federal statutory income tax rate to loss before income taxes is as follows (in thousands):
		Year Ended December 31,
		2013			2012
	Income tax benefit at federal statutory rate	$	(7,544	)	$	(2,878	)
	State taxes (net of federal)		186			(648	)
	Credits		—			(662	)
	Other		43			(842	)
	Collaboration arrangement acquisition cost		5,580			—
	Change in valuation allowance		1,735			5,030
	Total	$	—		$	—

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Results of Operations	'
	Following is a summary of the quarterly results of operations for the years ended December 31, 2013 and 2012 (in thousands, except per share amounts):
		March 31,			June 30,			September 30,			December 31,
		2013			2013			2013			2013
	Total revenue	$	279		$	248		$	4,552		$	4,638
	Operating expenses:
	Research and development		1,984			1,423			1,593			3,884
	General and administrative		1,220			1,118			1,463			974
	Collaboration arrangement acquisition cost		—			—			15,943			—
	Restructuring and asset impairment		7			7			7			6
	Total expenses		3,211			2,548			19,006			4,864
	Loss from operations		(2,932	)		(2,300	)		(14,454	)		(226	)
	Interest expense, net		(392	)		(406	)		(420	)		(425	)
	Other expense		(1	)		(4	)		—			(4	)
	Loss before income taxes		(3,325	)		(2,710	)		(14,874	)		(655	)
	Income tax provision		—			—			—			—
	Net loss	$	(3,325	)	$	(2,710	)	$	(14,874	)	$	(655	)
	Basic and diluted net loss per common share	$	(0.01	)	$	(0.01	)	$	(0.04	)	$	(0.00	)
	Shares used in computing basic and diluted net loss per common share		249,941			250,417			374,126			586,391
		March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012
	Total revenues	$	282		$	240		$	262		$	223
	Operating expenses:
	Research and development		786			700			818			1,477
	General and administrative		1,083			913			1,013			887
	Restructuring and asset impairment		9			9			8			8
	Total expenses		1,878			1,622			1,839			2,372
	Loss from operations		(1,596	)		(1,382	)		(1,577	)		(2,149	)
	Interest expense, net		(366	)		(379	)		(381	)		(394	)
	Other income (expense)		2			—			(4	)		—
	Loss before income taxes		(1,960	)		(1,761	)		(1,962	)		(2,543	)
	Income tax provision		(1	)		—			—			—
	Net loss	$	(1,961	)	$	(1,761	)	$	(1,962	)	$	(2,543	)
	Basic and diluted net loss per common share	$	(0.01	)	$	(0.01	)	$	(0.01	)	$	(0.01	)
	Shares used in computing basic and diluted net loss per common share		197,923			198,406			198,670			201,137

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Segment
Summary Of Organization And Operations [Line Items]	'	'	'
Number of operating segment	1	'	'
Accumulated deficit	($392,924,000)	($371,360,000)	'
Working capital	42,400,000	'	'
Shareholders' equity	33,683,000	-1,441,000	689,000
Cash and cash equivalents	$48,131,000	$7,414,000	$2,148,000
Restricted stock [Member]	'	'	'
Summary Of Organization And Operations [Line Items]	'	'	'
Unvested restricted stock awards	769,000	1,453,000	'

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)	12 Months Ended
	Dec. 31, 2013
Minimum [Member] | Computer equipment and software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'3 years
Minimum [Member] | Furniture and fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Minimum [Member] | Lab equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Minimum [Member] | Leasehold improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Maximum [Member] | Computer equipment and software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Maximum [Member] | Furniture and fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'7 years
Maximum [Member] | Lab equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'7 years
Maximum [Member] | Machinery and equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'5 years
Maximum [Member] | Leasehold improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, plant and equipment, estimated useful life	'17 years

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities (Detail)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Stock options plan [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities excluded from the calculation of diluted net loss per common share	7,766	6,755
Restricted stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities excluded from the calculation of diluted net loss per common share	769	1,453
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Securities excluded from the calculation of diluted net loss per common share	2,841	2,841

Cash_Cash_Equivalents_and_Shor2

Cash, Cash Equivalents and Short-term Investments - Summary of Cash and Cash Equivalents and Short-term Investments (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Cash and Cash Equivalents [Line Items]	'	'
Amortized Cost	'	$7,617
Gross Unrealized Gain	'	'
Gross Unrealized (Loss)	'	'
Estimated Fair Value	'	7,617
Cash and cash equivalents [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Amortized Cost	48,131	7,414
Gross Unrealized Gain	'	'
Gross Unrealized (Loss)	'	'
Estimated Fair Value	48,131	7,414
U.S. Treasury notes [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Amortized Cost	'	203
Gross Unrealized Gain	'	'
Gross Unrealized (Loss)	'	'
Estimated Fair Value	'	$203

Cash_Cash_Equivalents_and_Shor3

Cash, Cash Equivalents and Short-term Investments - Additional Information (Detail) (Maximum [Member], Short-term investments [Member])	12 Months Ended
	Dec. 31, 2012
Maximum [Member] | Short-term investments [Member]	'
Cash and Cash Equivalents [Line Items]	'
Short-term investment maturity period	'1 year

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) (Recurring [Member], USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	$48,131
Level 1 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	48,131
Level 2 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	'
Level 3 [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Cash and cash equivalents	'

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$12,183	$12,140
Less accumulated depreciation and amortization	-11,783	-11,413
Property and equipment, net	400	727
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	4,412	4,385
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	1,138	1,138
Lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	2,138	2,138
Computer equipment and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	2,651	2,640
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment	$1,844	$1,839

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property Plant And Equipment [Abstract]	'	'
Depreciation expense	$370	$391

Sublease_Agreement_and_Lease_E2

Sublease Agreement and Lease Exit Liability - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2007	Dec. 31, 2012	Dec. 31, 2011	Jan. 31, 2012	Apr. 30, 2009	Jul. 18, 2007	Jul. 18, 2007
					Mendel [Member]	Mendel [Member]	Mendel [Member]	3929 Point Eden Way, Hayward, CA [Member]
					sqft	sqft	sqft	sqft
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'	'
Number of square feet	'	'	'	'	3,300	1,550	48,000	72,000
Lease agreement initiation date	18-Jul-07	'	'	'	'	'	'	'
Impairment expense related to the sublease	'	$2,100,000	'	'	'	'	'	'
Lease exit current liability	168,000	'	144,000	'	'	'	'	'
Lease exit liability	297,000	'	465,000	'	'	'	'	'
Lease exit non-current liability	$465,000	'	$609,000	$729,000	'	'	'	'

Sublease_Agreement_and_Lease_E3

Sublease Agreement and Lease Exit Liability - Schedule of Lease Exit Liability Activity (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]	'	'
Balance at beginning of year	$609	$729
Accretion expense	26	34
Lease payments	-170	-154
Balance at end of the year	$465	$609

Collaboration_Agreement_Additi

Collaboration Agreement - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Aug. 27, 2013

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Aug. 31, 2013

Jul. 15, 2013

20-May-13

Dec. 31, 2012

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 27, 2013

Dec. 31, 2013

20-May-13

20-May-13

Maximum [Member]

License Agreement with Grifols [Member]

License Agreement with Grifols [Member]

License Agreement with Grifols [Member]

License Agreement with Grifols [Member]

License Agreement with Grifols [Member]

License Agreement with Grifols [Member]

Governance Agreement [Member]

Grifols [Member]

Grifols [Member]

Grifols [Member]

Investors [Member]

Minimum [Member]

Maximum [Member]

Research and development [Member]

General and administrative [Member]

Person

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20-May-13

'

'

Common stock, shares issued and sell

'

587,252,904

'

'

'

587,252,904

'

'

333,968,104

251,346,385

'

'

'

'

'

'

'

'

'

'

209,774,558

124,193,546

Common stock, purchase price per share

'

'

'

'

'

'

'

'

$0.12

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock

'

$426,607,000

'

'

'

$426,607,000

$41,400,000

'

'

$369,919,000

$41,400,000

'

'

'

'

'

'

'

'

'

'

'

Common Stock authorized shares

'

1,001,830,627

'

'

'

1,001,830,627

'

706,830,627

'

297,527,214

'

'

'

'

'

'

'

'

'

'

'

'

Shareholders holding percentage

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment received from investors and related party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,000,000

'

'

Closing price of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.20

'

'

'

Common stock discount per share

$0.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock discount on share

'

'

15,943,000

'

'

15,943,000

'

'

'

'

'

'

'

'

'

'

'

'

15,900,000

'

'

'

Future reimbursable research and development expenses by partner

'

'

'

'

'

'

'

'

'

'

'

65,000,000

'

'

'

'

'

'

'

'

'

'

Payments for development milestones by partner

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

Royalty payments on net sales rate

'

'

'

'

'

'

'

'

'

'

'

'

'

12.50%

20.00%

'

'

'

'

'

'

'

Patent coverage or orphan drug designation period

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

Percentage of reduction on royalty payment

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

Revenue recognized

'

'

'

'

'

8,672,000

'

'

'

'

'

8,700,000

'

'

'

'

'

'

'

'

'

'

Deferred revenue balance

'

'

'

'

'

'

'

'

'

'

'

4,400,000

'

'

'

'

'

'

'

'

'

'

Fully burdened development expenses

'

'

'

'

'

'

'

'

'

'

'

7,600,000

1,100,000

'

'

'

'

'

'

'

'

'

Revenues recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,100,000

$1,100,000

'

'

'

'

'

Number of independent directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

Number of directors designated by partner

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

Number of chief executive officer

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

Period to be consider after the first commercial sale for restriction to acquire and sale of stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 months

'

'

'

'

Minimum target percentage of beneficial ownership to be maintain under governance agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

Royalty_Agreement_Note_Payable1

Royalty Agreement, Note Payable, and Accrued Interest - Additional Information (Detail) (USD $)	1 Months Ended		12 Months Ended
	Jun. 30, 2011	Aug. 31, 2006	Dec. 31, 2013	Dec. 31, 2012
		Patents
Debt Instrument [Line Items]	'	'	'	'
U.S. patents along with foreign counterparts	'	12	'	'
Quarterly royalty payments rate	'	'	3.00%	'
Royalty revenue	'	'	$1,045,000	$1,007,000
Royalty financing agreement with a syndicate of lenders	8,500,000	'	9,035,000	8,513,000
Royalty financing agreement fees and expenses	473,000	'	'	'
Additional Interest Reserve Account	250,000	'	'	'
Royalties payable rate	100.00%	'	'	'
Term Loan accrue interest to LIBOR or plus	'A) LIBOR or b) 1.50%, plus a margin of 14.5%	'	'	'
Term Loan, base interest rate	1.50%	'	'	'
Term Loan, basis spread on base rate	14.50%	'	'	'
Accrued interest paid to cure the breach	'	'	'	167,000
Cumulative cash shortfall agreement from default stands	'	'	525,000	'
Capitalization of fees expenses	473,000	'	'	'
Amortization period of interest expenses	'48 months	'	'	'
Number of trading days for the average closing price	'10 days	'	'	'
Warrants expiration date	31-Dec-16	'	'	'
Discount interest rate	18.70%	'	'	'
Capital expenses amortized to interest expense for how many months	'48 months	'	'	'
Common stock [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Lender warrants to purchase common stock	2,840,909	'	'	'
Warrants [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Class of warrant or right, exercise price of warrants or rights	0.22	'	'	'
Common stock premium rate	20.00%	'	'	'
Warrants accounted for equity instruments, fair value, discount against note	$390,000	'	'	'

Leases_Commitments_and_Conting2

Leases, Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2012	Apr. 30, 2009	Jul. 18, 2007	Jul. 18, 2007
	LegalMatter		Mendel [Member]	Mendel [Member]	Mendel [Member]	3929 Point Eden Way, Hayward, CA [Member]
			sqft	sqft	sqft	sqft
Future Minimum Lease Payments Under Noncancellable Operating Leases [Line Items]	'	'	'	'	'	'
Lease expiration year	'2016	'	'	'	'	'
Number of square feet	'	'	3,300	1,550	48,000	72,000
Sublease commencement period	'2007-07	'	'	'	'	'
Total monthly base rent payments by Mendel	$3,000,000	'	'	'	'	'
Deferred rent	132,000	144,000	'	'	'	'
Building rent expense	594,000	600,000	'	'	'	'
Payments related to indemnifications	0	0	'	'	'	'
Liabilities related to indemnifications obligation	$0	$0	'	'	'	'
Claims or pending litigation	0	'	'	'	'	'

Leases_Commitments_and_Conting3

Leases, Commitments and Contingencies - Future Minimum Non-Cancelable Lease Payments (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2014, Operating Leases	$1,844
2015, Operating Leases	1,917
2016, Operating Leases	1,020
Total minimum lease payments, Operating Leases	4,781
2014, Mendel Sub-Lease	-1,167
2015, Mendel Sub-Lease	-1,201
2016, Mendel Sub-Lease	-640
Total minimum lease payments, Mendel Sub-Lease	-3,008
2014, Net Operating Lease Payments	677
2015, Net Operating Lease Payments	716
2016, Net Operating Lease Payments	380
Total minimum lease payments, Net Operating Lease Payments	$1,773

Shareholders_Equity_Deficit_Ad

Shareholders' Equity (Deficit) - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jul. 31, 2013

31-May-10

31-May-08

Jun. 30, 2007

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2013

20-May-13

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Apr. 30, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

20-May-13

20-May-13

Dec. 31, 2003

Dec. 31, 2003

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 1996

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

31-May-05

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Stock Option [Member]

Stock Option [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Restricted stock [Member]

Restricted stock [Member]

Stock options plan [Member]

Restricted stock units [Member]

Grifols [Member]

Grifols [Member]

Investors [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

1996 Plan [Member]

1996 Plan [Member]

1996 Plan [Member]

2005 [Member]

2005 [Member]

2005 [Member]

2005 [Member]

1996 Non-Employee Directors Plan [Member]

1996 Non-Employee Directors Plan [Member]

1996 Non-Employee Directors Plan [Member]

Warrants [Member]

Employee Stock Purchase Plan [Member]

Stock Option [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Purchase Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20-May-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued and sell

'

'

'

'

587,252,904

251,346,385

'

333,968,104

'

'

'

'

'

'

'

'

'

'

'

209,774,558

124,193,546

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, purchase price per share

'

'

'

'

'

'

'

$0.12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock

'

'

'

'

$426,607,000

$369,919,000

$41,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$41,400,000

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from private offering of common stock, net

'

'

'

'

40,227,000

5,547,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserves

'

'

'

'

7,766,300

'

'

'

'

'

'

'

2,688,643

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,840,909

Shares reserved for future grants

'

'

'

'

40,869,591

2,954,024

'

'

750,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

960,000

0

'

'

919,386

0

0

'

'

'

Number of right for each share of common stock outstanding

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rights expiration date

'

'

'

'

8-Sep-18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares available for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of issued and outstanding shares of common stock

'

'

'

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding

'

'

'

'

7,766,300

6,755,200

'

'

6,843,508

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110,000

'

'

7,656,300

'

'

'

0

'

'

'

Common stock authorized for issuance

'

'

'

'

2,918,638

'

'

'

'

'

'

'

2,688,643

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, net of cancelled or expired options

'

'

'

'

1,999,252

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock authorized

40,000,000

4,000,000

2,700,000

1,600,000

40,000,000

4,000,000

'

'

'

'

'

1,000,000

2,500,000

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000

'

Options granted expiration

'

'

'

'

'3 months 26 days

'

'

'

'

'

'

'

'

'

'

'

'2 years 9 months 4 days

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'10 years

'

'

'

Incentive and non-statutory stock option grants option price

'

'

'

'

110.00%

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

Non-statutory stock option grants option price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

Combined voting power

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares acquired vest period

'

'

'

'

'5 years

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

Outstanding notes receivables

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

Options granted

'

'

'

'

1,170,000

560,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,170,000

560,000

'

'

670,000

560,000

'

'

Number of shares repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

Option price, fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

'

'

'

Aggregate intrinsic value of stock options outstanding

'

'

'

'

'

'

'

'

'

45,000

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options exercised

'

'

'

'

10,000

'

'

'

'

10,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock exercisable

'

'

'

'

'

'

'

'

'

7,028,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of common stock exercisable

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of restricted stock awards vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

307,000

185,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company retained purchase rights on unvested restricted stock awards, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

769,000

1,453,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee stock-based compensation expense for restricted stock awards

'

'

'

'

421,000

473,000

'

'

'

'

'

'

'

'

215,000

236,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of a restricted stock unit

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

78,947

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of days employees have to continuously employed to participate in the Employee Stock Purchase Plan

'

'

'

'

'

'

'

'

'

'

'

'

'10 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Customary employment weekly period required to participate in the ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'20 hours

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum period employee required to work per calendar year to participate in ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'5 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condition given to employees to participate in ESPP

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of limitation of Employee contributions, through payroll deductions to lessor

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Limitation of Employee contributions, through payroll deductions to lessor

'

'

'

'

17,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

Number of Shares issued under the ESPP

'

'

'

'

'

'

'

'

'

'

'

'

4,361,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

106,000

57,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Capitalized stock-based employee compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Tax benefit associated with stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Recognized compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

88,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost

'

'

'

'

$106,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term of options granted

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

'

'

'

0.00%

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shareholders_Equity_Deficit_Sc

Shareholders' Equity (Deficit) - Schedule of Share Based Compensation Activity (Detail) (USD $)	1 Months Ended				12 Months Ended
	Jul. 31, 2013	31-May-10	31-May-08	Jun. 30, 2007	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Shares Available for Grant of Option or Award, Beginning balance	'	'	'	'	2,954,024	750,133
Options granted, Shares Available for Grant of Option or Award	'	'	'	'	-1,170,000	-560,000
Increase in authorized shares, Shares Available for Grant of Option or Award	40,000,000	4,000,000	2,700,000	1,600,000	40,000,000	4,000,000
Options cancelled, Shares Available for Grant of Option, Award or Unit	'	'	'	'	148,900	648,308
Options exercised, Shares Available for Grant of Option, Award or Unit	'	'	'	'	'	'
Restricted share awards cancelled, Shares Available for Grant of Options or Award	'	'	'	'	150,000	'
Shares Available for Grant of Option or Award, Ending balance	'	'	'	'	40,869,591	2,954,024
Number of Shares, Beginning balance	'	'	'	'	6,755,200	6,843,508
Options granted, Number of Shares	'	'	'	'	1,170,000	560,000
Options cancelled, Number of Shares	'	'	'	'	-148,900	-648,308
Options exercised, Number of Shares	'	'	'	'	-10,000	'
Number of Shares, Ending balance	'	'	'	'	7,766,300	6,755,200
Weighted Average Exercise Price, Beginning balance	'	'	'	'	$0.83	$1.05
Options granted, Weighted Average Exercise Price	'	'	'	'	$0.16	$0.15
Options cancelled, Weighted Average Exercise Price	'	'	'	'	$1.92	$2.52
Options Exercised, Weighted Average Exercise Price	'	'	'	'	$0.16	'
Weighted Average Exercise Price, Ending balance	'	'	'	'	$0.71	$0.83
Restricted stock [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Restricted stock awards granted, Shares Available for Grant of Option or Award	'	'	'	'	-1,213,333	-1,884,417
Minimum [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Price per Share, Beginning Balance	'	'	'	'	$0.12	$0.12
Options granted, Price per Share	'	'	'	'	$0.12	$0.15
Options cancelled, Price per Share	'	'	'	'	$0.15	$0.13
Options exercised, Price per Share	'	'	'	'	$0.16	'
Price per Share, Ending Balance	'	'	'	'	$0.12	$0.12
Maximum [Member]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Price per Share, Beginning Balance	'	'	'	'	$12	$24.10
Options granted, Price per Share	'	'	'	'	$0.20	$0.15
Options cancelled, Price per Share	'	'	'	'	$10.80	$24.10
Options exercised, Price per Share	'	'	'	'	$0.16	'
Price per Share, Ending Balance	'	'	'	'	$12	$12

Shareholders_Equity_Deficit_Su

Shareholders' Equity (Deficit) - Summary of Stock Options Outstanding and Exercisable (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number Of Shares	7,766,300
Weighted Average Remaining Contractual Life (In Years)	'5 years 6 months
Weighted Average Exercise Price	$0.71
Options Exercisable, Number of Shares	7,028,800
Options Exercisable, Weighted Average Exercise Price	$0.77
Range One [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$0.13
Exercise Price Range Lower Limit	$0.12
Number Of Shares	370,000
Weighted Average Remaining Contractual Life (In Years)	'6 years 10 months 24 days
Weighted Average Exercise Price	$0.12
Options Exercisable, Number of Shares	355,000
Options Exercisable, Weighted Average Exercise Price	$0.12
Range Two [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$0.15
Exercise Price Range Lower Limit	$0.15
Number Of Shares	1,071,000
Weighted Average Remaining Contractual Life (In Years)	'7 years 8 months 9 days
Weighted Average Exercise Price	$0.15
Options Exercisable, Number of Shares	861,000
Options Exercisable, Weighted Average Exercise Price	$0.15
Range Three [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$0.17
Exercise Price Range Lower Limit	$0.16
Number Of Shares	1,233,000
Weighted Average Remaining Contractual Life (In Years)	'7 years 6 months
Weighted Average Exercise Price	$0.17
Options Exercisable, Number of Shares	733,000
Options Exercisable, Weighted Average Exercise Price	$0.16
Range Four [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$0.18
Exercise Price Range Lower Limit	$0.18
Number Of Shares	1,344,000
Weighted Average Remaining Contractual Life (In Years)	'6 years
Weighted Average Exercise Price	$0.18
Options Exercisable, Number of Shares	1,344,000
Options Exercisable, Weighted Average Exercise Price	$0.18
Range Five [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$0.25
Exercise Price Range Lower Limit	$0.19
Number Of Shares	1,211,500
Weighted Average Remaining Contractual Life (In Years)	'5 years 4 months 28 days
Weighted Average Exercise Price	$0.23
Options Exercisable, Number of Shares	1,199,000
Options Exercisable, Weighted Average Exercise Price	$0.23
Range Six [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$1.60
Exercise Price Range Lower Limit	$0.39
Number Of Shares	1,347,800
Weighted Average Remaining Contractual Life (In Years)	'3 years 10 months 21 days
Weighted Average Exercise Price	$1.26
Options Exercisable, Number of Shares	1,347,800
Options Exercisable, Weighted Average Exercise Price	$1.26
Range Seven [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$1.87
Exercise Price Range Lower Limit	$1.64
Number Of Shares	999,000
Weighted Average Remaining Contractual Life (In Years)	'2 years 6 months 26 days
Weighted Average Exercise Price	$1.80
Options Exercisable, Number of Shares	999,000
Options Exercisable, Weighted Average Exercise Price	$1.80
Range Eight [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$6.90
Exercise Price Range Lower Limit	$3.14
Number Of Shares	156,000
Weighted Average Remaining Contractual Life (In Years)	'2 years 6 months 26 days
Weighted Average Exercise Price	$4.77
Options Exercisable, Number of Shares	156,000
Options Exercisable, Weighted Average Exercise Price	$4.77
Range Nine [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$7.95
Exercise Price Range Lower Limit	$7.95
Number Of Shares	12,000
Weighted Average Remaining Contractual Life (In Years)	'1 year 26 days
Weighted Average Exercise Price	$7.95
Options Exercisable, Number of Shares	12,000
Options Exercisable, Weighted Average Exercise Price	$7.95
Range Ten [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Exercise Price Range Upper Limit	$12
Exercise Price Range Lower Limit	$12
Number Of Shares	22,000
Weighted Average Remaining Contractual Life (In Years)	'1 month 28 days
Weighted Average Exercise Price	$12
Options Exercisable, Number of Shares	22,000
Options Exercisable, Weighted Average Exercise Price	$12

Shareholders_Equity_Deficit_Sc1

Shareholders' Equity (Deficit) - Schedule of Unvested Restricted Stock and Performance Bonus Stock Award (Detail) (Unvested restricted stock awards [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Unvested restricted stock awards [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Beginning Balance, Number of Shares	1,453,084	938,976
Restricted stock awards granted, Number of shares	1,213,333	1,884,417
Restricted share awards canceled, Number of shares	-150,000	'
Restricted share awards vested, Number of shares	-1,747,750	-1,370,309
Ending Balance, Number of Shares	768,667	1,453,084
Beginning Balance, Weighted Average Grant Date Fair Value	$0.14	$0.19
Restricted stock awards granted, Weighted Average Grant Date Fair Value	$0.16	$0.14
Restricted share awards cancelled, Weighted Average Grant Date Fair Value	$0.15	'
Restricted share awards vested, Weighted Average Grant Date Fair Value	$0.14	$0.16
Ending Balance, Weighted Average Grant Date Fair Value	$0.18	$0.14

Shareholders_Equity_Deficit_Em

Shareholders' Equity (Deficit) - Employee Stock Purchase Plan (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee stock purchase plan	'	'
Dividend yield	0.00%	'
Employee Stock Purchase Plan [Member]	'	'
Employee stock purchase plan	'	'
Dividend yield	0.00%	0.00%
Volatility factor	245.10%	105.30%
Risk-free interest rate	0.20%	1.00%
Expected life (years)	'2 years	'2 years
Weighted-average fair value of purchase rights granted during the period	$0.14	$0.12

Shareholders_Equity_Deficit_Sc2

Shareholders' Equity (Deficit) - Schedule of Stock Based Compensation Expenses (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Costs and Expenses	'	'
Total employee stock-based compensation expense	$421,000	$473,000
Impact on basic and diluted net loss per common share	$0	$0
Research and development [Member]	'	'
Costs and Expenses	'	'
Total employee stock-based compensation expense	138,000	102,000
General and administrative [Member]	'	'
Costs and Expenses	'	'
Total employee stock-based compensation expense	$283,000	$371,000

Shareholders_Equity_Deficit_Sc3

Shareholders' Equity (Deficit) - Schedule of Stock Based Compensation Valuation Assumption (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Valuation assumption	'	'
Dividend yield	0.00%	'
Stock Option [Member]	'	'
Valuation assumption	'	'
Dividend yield	0.00%	0.00%
Volatility factor	173.00%	172.00%
Risk-free interest rate	1.40%	0.80%
Expected life (years)	'5 years 8 months 12 days	'5 years 3 months 18 days
Weighted-average fair value of options granted during the periods	$0.15	$0.14

Employee_Benefit_Plans_Additio

Employee Benefit Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'
Employee's contribution on pretax basis	$17,500	'
Additional contribution of employees above 50 years	5,500	'
Employer matching contribution expense	$40,000	$10,000
Maximum [Member]	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Percentage of employees' matching contributions	3.00%	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended					12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]	'	'	'	'	'	'	'
Income Tax Benefit	'	'	'	'	$1,000	$0	$0
Valuation allowance on deferred tax assets	'	'	'	'	'	1,735,000	5,030,000
California research and development tax credit carryforwards	6,509,000	'	'	'	'	6,509,000	6,509,000
Unrecognized tax benefits	0	'	'	'	'	0	'
Interest and penalties accrued on unrecognized tax benefits	0	'	'	'	'	0	'
General Business Tax Credit Carryforward [Member]	'	'	'	'	'	'	'
Income Tax [Line Items]	'	'	'	'	'	'	'
Tax credit carryforward, amount	7,200,000	'	'	'	'	7,200,000	'
CALIFORNIA	'	'	'	'	'	'	'
Income Tax [Line Items]	'	'	'	'	'	'	'
California net operating loss carryforwards expiration period	'	'	'	'	'	'2014 through 2033	'
California net operating loss carryforwards	40,100,000	'	'	'	'	40,100,000	'
State and Local Jurisdiction [Member]	'	'	'	'	'	'	'
Income Tax [Line Items]	'	'	'	'	'	'	'
California net operating loss carryforwards	40,100,000	'	'	'	'	40,100,000	'
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]	'	'	'	'	'	'	'
Income Tax [Line Items]	'	'	'	'	'	'	'
California research and development tax credit carryforwards	10,000,000	'	'	'	'	10,000,000	'
Domestic Tax Authority [Member]	'	'	'	'	'	'	'
Income Tax [Line Items]	'	'	'	'	'	'	'
Federal net operating loss carryforwards	41,200,000	'	'	'	'	41,200,000	'
Tax credit carryforward, amount	$7,300,000	'	'	'	'	$7,300,000	'
California net operating loss carryforwards expiration period	'	'	'	'	'	'2019 through 2032	'

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryforwards	$16,739	$14,332
Research and development credits	6,509	6,509
Federal orphan drug credits	7,228	7,228
Other	1,210	1,881
Total deferred tax assets	31,686	29,950
Valuation allowance	-31,686	-29,950
Net deferred tax assets	'	'

Income_Taxes_Schedule_of_Diffe

Income Taxes - Schedule of Difference Between Income Tax Benefit and Computation Amount of Federal Statutory Income Tax Rate (Detail) (USD $)	3 Months Ended					12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'
Income tax benefit at federal statutory rate	'	'	'	'	'	($7,544)	($2,878)
State taxes (net of federal)	'	'	'	'	'	186	-648
Credits	'	'	'	'	'	'	-662
Other	'	'	'	'	'	43	-842
Collaboration arrangement acquisition cost	'	'	'	'	'	5,580	'
Change in valuation allowance	'	'	'	'	'	1,735	5,030
Total	'	'	'	'	$1	$0	$0

Quarterly_Results_of_Operation2

Quarterly Results of Operations - Summary of Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]	'	'	'	'	'	'	'	'	'	'
Total revenue	$4,638	$4,552	$248	$279	$223	$262	$240	$282	$9,717	$1,007
Operating expenses:	'	'	'	'	'	'	'	'	'	'
Research and development	3,884	1,593	1,423	1,984	1,477	818	700	786	8,884	3,781
General and administrative	974	1,463	1,118	1,220	887	1,013	913	1,083	4,775	3,896
Collaboration arrangement acquisition cost	'	15,943	'	'	'	'	'	'	15,943	'
Restructuring and asset impairment	6	7	7	7	8	8	9	9	27	34
Total operating expenses	4,864	19,006	2,548	3,211	2,372	1,839	1,622	1,878	29,629	7,711
Loss from operations	-226	-14,454	-2,300	-2,932	-2,149	-1,577	-1,382	-1,596	-19,912	-6,704
Interest expense, net	-425	-420	-406	-392	-394	-381	-379	-366	'	'
Other income (expense)	-4	'	-4	-1	'	-4	'	2	-9	-2
Loss before income taxes	-655	-14,874	-2,710	-3,325	-2,543	-1,962	-1,761	-1,960	'	'
Income tax provision	'	'	'	'	'	'	'	-1	0	0
Net loss	($655)	($14,874)	($2,710)	($3,325)	($2,543)	($1,962)	($1,761)	($1,961)	($21,564)	($8,226)
Basic and diluted net loss per common share	$0	($0.04)	($0.01)	($0.01)	($0.01)	($0.01)	($0.01)	($0.01)	($0.06)	($0.04)
Shares used in computing basic and diluted net loss per common share	586,391	374,126	250,417	249,941	201,137	198,670	198,406	197,923	366,165	201,310